

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
2 September 2004 (02.09.2004)

PCT

(10) International Publication Number  
**WO 2004/073599 A2**

(51) International Patent Classification<sup>7</sup>: **A61K**

(21) International Application Number: **PCT/IB2004/000403**

(22) International Filing Date: 6 February 2004 (06.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/448,253 18 February 2003 (18.02.2003) US

(71) Applicant (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DUGGAL, Rohit** [IN/US]; Agouron Pharmaceuticals Inc., 10777 Science Center Drive, San Diego, CA 92121 (US). **PATICK, Amy, Karen** [US/US]; Agouron Pharmaceuticals Inc., 10777 Science Center Drive, San Diego, CA 92121 (US). **ZHAO, Weldong** [CN/US]; Agouron Pharmaceuticals Inc., 10777 Science Center Drive, San Diego, CA 92121 (US). **HER-LIHY, Koleen, Jill** [US/US]; Agouron Pharmaceuticals Inc., 10777 Science Center Drive, San Diego, CA 92121 (US). **SHA, Elann** [US/US]; Agouron Pharmaceuticals Inc., 10777 Science Center Drive, San Diego, CA 92121 (US). **LIU, Wei** [US/US]; Agouron Pharmaceuticals Inc., 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agents: **LUMB, J., Trevor et al.**; Pfizer Inc., c/o Jackie Lawrence, Eastern Point Road (MS 8260-1615), Groton, CT 06340 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/073599 A2

(54) Title: INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME

(57) Abstract: The invention relates to methods of inhibiting HCV viral replication activity comprising contacting an HCV polymerase with a therapeutically effective amount of a hydroxamate MMP inhibitor, and composition comprising the same.

**INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME**

**Field of The Invention**

5 The Invention relates to methods of inhibiting HCV viral replication activity comprising contacting an HCV polymerase with a therapeutically effective amount of a hydroxamate MMP inhibitor. The Invention further relates to pharmaceutical compositions containing the hydroxamate MMP inhibitor in a mammal by administering effective amounts of such hydroxamate MMP inhibitor.

10 **Background of The Invention**

Hepatitis C virus (HCV) is a member of the hepacivirus genus in the family *Flaviviridae*. It is the major causative agent of non-A, non-B viral hepatitis and is the major cause of transfusion-associated hepatitis and accounts for a significant proportion of hepatitis cases worldwide. Although acute HCV infection is often asymptomatic, nearly 80% of cases 15 resolve to chronic hepatitis. The persistent property of the HCV infection has been explained by its ability to escape from the host immune surveillance through hypermutability of the exposed regions in the envelope protein E2 (Welner et al., *Virology* 180:842-848 (1991); Weiner et al. *Proc. Natl. Acad. Sci. USA* 89:3468-3472 (1992)).

HCV is an enveloped RNA virus containing a single-stranded positive-sense RNA 20 genome approximately 9.5 kb in length (Choo et al., *Science* 244:359-362 (1989)). The RNA genome contains a 5'-nontranslated region (5' NTR) of 341 nucleotides (Brown et al., *Nucl. Acids Res.* 20:5041-5045 (1992); Bukh et al., *Proc. Natl. Acad. Sci. USA* 89:4942-4946 (1992)), a large open reading frame (ORF) encoding a single polypeptide of 3,010 to 3,040 25 amino acids (Choo et al. (1989), *supra*), and a 3'-nontranslated region (3'-NTR) of variable length of about 230 nucleotides (Kolykhalov et al., *J. Virol.* 70:3363-3371 (1996); Tanaka et al., *J. Virol.* 70:3307-3312 (1996)).

The 5' NTR is one of the most conserved regions of the viral genome and plays a pivotal role in the initiation of translation of the viral polyprotein (Bartenschlager (1997), *supra*). A single long ORF encodes a polyprotein, which is co- or post-translationally 30 processed into structural (core, E1, and E2) and nonstructural (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) viral proteins by either cellular or viral proteinases (Bartenschlager (1997), *supra*). The 3' NTR consists of three distinct regions: a variable region of about 38 nucleotides following the stop codon of the polyprotein, a polyuridine tract of variable length with interspersed substitutions of cytidines, and 98 nucleotides (nt) at the very 3' end which 35 are highly conserved among various HCV isolates. The order of the genes within the genome is: NH<sub>2</sub>-C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH (Grakoui et al., *J. Virol.* 67:1385-1395 (1993)).

Processing of the structural proteins core (C), envelope protein 1 and (E1, E2), and the p7 region is mediated by host signal peptidases. In contrast, maturation of the nonstructural (NS) region is accomplished by two viral enzymes. The HCV polyprotein is first cleaved by a host signal peptidase generating the structural proteins C/E1, E1/E2, E2/p7, and 5 p7/NS2 (Hijikata et al., *Proc. Natl. Acad. Sci. USA* 88:5547-5551 (1991); Lin et al., *J. Virol.* 68:5063-5073 (1994)). The NS2-3 proteinase, which is a metalloprotease, then cleaves at the NS2/NS3 junction. The NS3/4A proteinase complex (NS3 being a serine protease and NS4A acting as a cofactor of the NS3 protease), is then responsible for processing at all the remaining sites (Bartenschlager et al., *J. Virol.* 67:3835-3844 (1993); Bartenschlager (1997), 10 *supra*). RNA helicase and NTPase activities have also been identified in the NS3 protein. The N-terminal one-third of the NS3 protein functions as a protease, and the remaining two-thirds of the molecule acts as the helicase/ATPase that is thought to be involved in HCV replication (Bartenschlager (1997), *supra*). NS4A is a cofactor for the NS3 protease and is followed by NS4B, for which the function is unknown. NS5A is a phosphorylated protein and 15 its function is currently unknown. The fourth viral enzyme, NS5B, is an RNA-dependent RNA polymerase (RdRp) and a key component responsible for replication of the viral RNA genome (Lohmann et al., *J. Virol.* 71:8416-8428 (1997)).

Since persistent infection of HCV is related to chronic hepatitis and eventually to hepatocarcinogenesis, HCV replication is one of the targets to eradicate HCV reproduction 20 and to prevent hepatocellular carcinoma. New treatment approaches for HCV infection include the development of prophylactic and therapeutic vaccines, the identification of interferons with improved pharmacokinetic characteristics, and the discovery of drugs designed to inhibit HCV replication.

Matrix metalloproteinases ("MMPs") are a family of enzymes, including, but not 25 limited to, collagenases, gelatinases, matrilysin, and stromelysins, which are involved in the degradation and remodelling of connective tissues. These enzymes are found in a number of cell types that are found in or associated with connective tissue, such as fibroblasts, monocytes, macrophages, endothelial cells and metastatic tumor cells. Matrix metalloproteinases degrade the protein components of the extracellular matrix, i.e. the protein 30 components found in the linings of joints, interstitial connective tissue, basement membranes, cartilage and the like. These proteins include collagen, proteoglycan, fibronectin and laminin.

Hydroxamate compounds are known as MMP inhibitors (see, e.g., U.S. Pat. Nos. 6,465,508; 6,462,042; 6,429,213; 6,365,587; 6,340,691; 6,268,379; 6,228,869; 6,197,795; 6,162,821; 5,977,408; 5,962,481; 5,929,097; 5,861,436; 5,804,593; 5,700,838; and 35 5,652,262). Each of these patents is herein incorporated by reference in their entirety.

Nonetheless, none of the hydroxamate MMP inhibitors are known to be HCV inhibitors that have desirable or improved physical and chemical properties appropriate for pharmaceutical applications for treating HCV indications.

Summary of The Invention

The present Invention provides a novel method of interfering with or preventing HCV viral replication activity comprising contacting an HCV polymerase with a therapeutically effective amount of a hydroxamate MMP inhibitor.

5 In one embodiment of the present Invention, the hydroxamate MMP inhibitor is administered orally or intravenously.

The present invention also provides a method of treating a condition that is mediated by HCV polymerase in a patient by administering to said patient a pharmaceutically effective amount of a hydroxamate MMP inhibitor.

10 The present Invention also provides a method of targeting MMP inhibition as a means of treating indications caused by HCV infections.

The present Invention also provides a method of targeting viral or cellular targets identified by using MMP Inhibitors for treating indications caused by HCV infections.


15 The present Invention also provides a method of identifying cellular or viral pathways interfering with the functioning of the members of which could be used for treating indications caused by HCV infections by administering an MMP inhibitor.

The present invention also provides a method of using MMP inhibitors as tools for understanding mechanism of action of other HCV inhibitors.


20 The present Invention also provides a method of using MMP inhibitors for carrying out gene profiling experiments for monitoring the up or down regulation of genes for the purpose of identifying inhibitors for treating indications caused by HCV infections.

The present Invention further provides a pharmaceutical composition for the treatment of Hepatitis C virus (HCV) in a mammal containing an amount of hydroxamate MMP inhibitor that is effective in treating HCV and a pharmaceutically acceptable carrier.

25 In one embodiment of the present Invention, the hydroxamate MMP inhibitors have the formula I:



wherein:




30 A is a bond, CONH, or

R¹ is alkyl, aryl, halo, amino, substituted or distributed amino, or alkoxy;

and the pharmaceutically acceptable salts thereof, see WO0004892.

In another embodiment of the present invention, the hydroxamate MMP inhibitors have the formula



wherein X is oxygen or  $\text{C}-\text{CH}_2-$ .

5 Other embodiments of the invention include those described in [WO0004892](#), incorporated herein in its entirety by reference.

In another embodiment of the present invention, the hydroxamate MMP Inhibitors are selected from the group consisting of

- 2-(2-Phenylethyl)benzoic acid N-hydroxyamide;
- 10 2-(Propylthio)-pyridine-3-N-(hydroxy)carboxamide; [4-(N-Hydroxyamino)-2R-isobutyl-3S-((thien-2-ylthio)methyl)succinyl]-L-phenylalanine-N-methylamide;
- N-Hydroxy-5-phenylpentanamide;
- 2-(Phenyl-2-ethyl)pyridine-3-N-hydroxycarboxamide;
- 15 2-(Thiobenzyl)benzoic acid N-hydroxy amide; 6-Biphenyl-4-yl-[2,2-dimethyl-1-(pyridin-4-ylcarbamoyl)-propylcarbamoyl]-hexanoic acid, N-hydroxyamide;
- 3R(6-(4-Biphenyl)-3-(N-benzylcarbamoyl))-hexanoic acid N-hydroxyamide;
- 2-Benzylsulfonyl-cyclopent-1-ene-carboxylic acid hydroxamide;
- 20 2-Benzylsulfonyl-cyclohex-1-enecarboxylic acid hydroxamide; 6-Benzylsulfonyl-cyclohex-1-enecarboxylic acid hydroxamide;
- 1-(N-Hydroxy)-3-(2-bibenzyl)urea;
- 3R-(6-(4-Biphenyl)propyl)-N-(3-methylpyridinecarbamoyl)- hexanoic acid N-hydroxy-amide;
- 4-(2-[(5-Hydroxyamino-3-(3-phenyl-propyl)-3,4-dihydro-2-H-pyrrole-3-carbonyl]-amino)-4-
- 25 methyl-pentanoylamino)benzolic acid methyl ester;
- 5-Hydroxyamino-3-(3-phenyl-propyl)-3,4-dihydro-2-H-pyrrole-3- carboxylic acid (2-cyclohexyl-1-methylcarbamoyl-ethyl) amide;
- 4-(2- { [5-Hydroxyamino-3-(3-pentyl)-3,4-dihydro-2-H-pyrrole-3-carbonyl]-amino}-4-methyl-pentanoylamino) benzolic acid methyl ester;
- 30 6-Biphenyl-4-yl-3-(R)-(2-hydroxy-1-hydroxymethyl-ethylcarbamoyl)-hexanehydroxamic acid;
- 6-Biphenyl-4-yl-3(R)-(1(S)-hydroxymethyl-2,2-dimethyl- propylcarbamoyl)- hexanehydroxamicacid;
- 2-(Biphenyl-4-ylsulfonyl)-cyclohex-1-enecarboxylic acid hydroxamide;
- 6-(Biphenyl-4-ylsulfonyl)-cyclohex-1-enecarboxylic acid hydroxamide;

2-Phenethylsulfanyl-cyclohex-1-enecarboxylic acid hydroxyamide;  
2-Benzylsulfanyl-cyclohexancarboxylic acid hydroxamide;  
trans-2-Benzylsulfanyl-cyclohexancarboxylic acid hydroxamide;  
trans-2-(Biphenyl-4-yl-methylsulfanyl)-cyclohexancarboxylic acid hydroxamide;  
5 6-Biphenyl-4-yl-3-(R)-(1-hydroxymethyl-2-(S)-(1H-imidazol-4-yl)-ethylcarbamoyl)-hexanehydroxamic acid;  
N-Hydroxy-2-[2-Oxo-3-(3-phenyl-propyl)-tetrahydro-furan-3-yl]-acetamide;  
trans-2-(4-Phenoxy-benzylsulfanyl)-cyclohexancarboxylic acid hydroxamide;  
2-(4-Indol-1-yl-benzylsulfanyl)-cyclohexancarboxylic acid hydroxamide;  
10 2-(3-Biphenyl-4-yl-propyl)-N4-hydroxy-N1-(2,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl)-succinamide;  
2-(2-Biphenyl-4-yl-ethylsulfanyl)-cyclohexane carboxylic acid hydroxyamide;  
2-(3-Biphenyl-4-yl-propyl)-N4-hydroxy-N1-(2-hydroxy-cyclohexyl)-succinamide;  
6-Biphenyl-4-yl-3-(1-hydroxyimino-ethyl)-hexanoic acid hydroxyamide;  
15 3-(R)-(2-Hydroxy-1-(S)-(1H-imidazol-4-yl)-ethylcarbamoyl)-6-(4-(2-methyl-thiazol-4-yl)-phenyl)-hexanehydroxamic acid;  
6-Biphenyl-4-yl-3-(3-hydroxy-piperidine-1-carbonyl)-hexanoic acid-hydroxyamide;  
1-(4-Methoxy-benzenesulfonyl)-piperidine-2-carboxylic acid hydroxamide;  
1-1-[4-Bromo-phenoxy]-benzenesulfonyl)-piperidine-2-carboxylic acid hydroxyamide;  
20 N-(1-benzyl-2-hydroxy-ethyl)-N4-hydroxy-2-isobutyl- succinamide;  
6-Biphenyl-4-yl-3 (R)-2 (S)-hydroxy-(1(S)-hydroxymethyl-2,2-dimethyl-propylcarbamoyl)-hexanoic hydroxamic acid;  
6-Biphenyl-4-yl-3-(2-hydroxy-1hydroxymethyl-propylcarbamoyl)- hexanoic hydroxamic acid;  
trans-2-(3-Biphenyl-4-yl-propyl)-cyclohexane carboxylic acid hydroxyamide;  
25 1-[4-Biphenyl-4-yloxy]-benzenesulfonyl)-piperidine-2-carboxylic acid hydroxamide;  
1-(4-Phenoxy-benzenesulfonyl)-piperidine-2-carboxylic acid hydroxamide;  
6-Biphenyl-4-yl-3-(R)-(1-(S)-hydroxymethyl-2-(3-pyridyl)- ethylcarbamoyl)-hexanehydroxamic acid;  
6-Biphenyl-4-yl-2S-hydroxy-3R-(1S-hydroxymethyl-3- methylsulfanyl-propylcarbamoyl)-  
30 hexanoic hydroxamic acid;  
1-[-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-4-(tertbutoxycarbonyl)-piperazine-2-carboxylic acid hydroxyamide;  
1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperazine-2-carboxylic acid hydroxyamide;  
4-Acetyl-1-[4-phenoxy-benzenesulfonyl]-piperazine-2-carboxylic acid, N-hydroxyamide;  
35 1-(Diphenylphosphinic)-piperidine-2-carboxylic acid hydroxamide;  
6-Biphenyl-4-yl-3-(R)-(2-oxo-1-tetrahydrofuran-3-(S)-ylcarbamoyl)-hexane hydroxamic acid;  
1-[-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-4-methyl-piperazine-2-carboxylic acid N-  
hydroxyamide;

4-(4-Methoxy-benzenesulfonyl)-thiomorpholine-3-carboxylic acid hydroxyamide;  
3-(Diphenylphosphinic)-propanoic acid hydroxyamide;  
1-[4-(4-Chlorophenoxy)benzenesulfonyl]-thiomorpholine-3-carbamoyl)piperazine-2-carboxamide;

5 4[4-Phenoxy-benzenesulfonyl]-piperazine-2-carboxylic acid, N-hydroxyamide;  
4[4-Phenoxy-benzenesulfonyl]-thiomorpholine-3-carboxylic acid N-hydroxyamide;  
3[2-Biphenyl-4-yl-ethylsulfanyl]-tetrahydro-pyran-4-carboxylic acid N-hydroxyamide;  
1-[4-Phenoxy-benzenesulfonyl]-4-methyl-piperazine-2-carboxylic acid N-hydroxyamide;  
6-Biphenyl-4-yl-3-(R)-(2-oxo-azepan-3-(S)-ylcarbamoyl)-hexane hydroxamic acid;

10 4-(1H-Indole-2-sulfonyl)-thiomorpholine-3-carboxylic acid hydroxyamide;  
1-(Methyl-phenylphosphinic)-piperidine-2-(R)-carboxylic acid hydroxamide;  
1-(1,3-Dihydro-isoindole-2-sulfonyl)-piperidine-2-carboxylic acid hydroxamide;  
4-Methyl-1-(4-(4-chlorophenyl)benzenesulfonyl)-N-hydroxy-2R- piperazinecarboxamide hydrochloride;

15 1-[4-Chlorophenoxybenzenesulfonyl]-N-hydroxy-2R-piperazinecarboxamide;  
2-(3-Phenyl-propylsulfonyl)-cyclohexane carboxylic acid hydroxamide;  
1-(Pyrrolidine-1-sulfonyl)-piperidine-2-carboxylic acid hydroxyamide;  
1-(Piperidine-1-sulfonyl)-piperidine-2-carboxylic acid hydroxyamide;  
4-[-[4-Bromo-phenoxy-benzenesulfonyl]-oxothiomorpholine-3-carboxylic acid-N-

20 hydroxyamide; -  
1-[4-(4-Methoxy-phenylsulfanyl)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;  
1-[4-(4-Cyano-phenoxy)-benzenesulfonyl]-4-(tert-butoxycarbonyl)-piperazine-2-carboxylic acid N-hydroxyamide;  
6-Oxo-3-(4-phenoxy-benzenesulfonyl)-hexahydro-pyrimidine-4- carboxylic acid hydroxamate;

25 4-(t-Butoxycarbonyl)-1-(4-(pyridin-2-yl)oxybenzenesulfonyl)-N- hydroxy-piperazine-2-carboxamide;  
4-[(4-Fluorophenoxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid N-hydroxyamide;  
4-[4-(Fluoro-phenoxy)-benzenesulfonyl]-oxothiomorpholine-3-carboxylic acid N-hydroxyamide;

30 4-(4-Butoxy-benzenesulfonyl)-thiomorpholine-3-carboxylic acid hydroxyamide;  
4-(4-Butoxy-benzenesulfonyl)-1-oxothiomorpholine-3-carboxylic acid hydroxyamide;  
1-[4-(4-Fluorophenyl)benzenesulfonyl]-4-(tert-butoxycarbonyl)2R-piperazine-2-carboxylic acid hydroxyamide;  
1-((4-(4-Chlorophenyl)-piperazine)--l-sulfonyl)-piperidine-2carboxylic acid hydroxamide;

35 35 cis-2-Phenethylsulfanyl-cyclohexanecarboxylic acid hydroxyamide;  
1-[-[4-(4-Fluorophenyl) benzenesulfonyl]-N-hydroxy-2R- piperazinecarboxamide hydrochloride;  
1-(Diphenylphosphinic)-pyrrolidine-2(R)-carboxylic acid hydroxyamide;

trans-2-Phenethylsulfonyl-cyclohexanecarboxylic acid hydroxyamide;  
1-[4-(4-Fluorophenyl)-piperazine- 1-sulfonyl]-piperidine-2- carboxylic acid hydroxyamide;  
1-1-[4-(4-Fluorophenylsulfanyl)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;  
4-1-[4-(Bromo-phenoxy)-benzenesulfonyl]-2, 2-dimethyl-1-oxo-thiomorpholine-3-carboxylic  
5 acid hydroxyamide;  
1-(Pyrrolidine-1-carbonyl)-pyrrolidine-2 (R)-carboxylic acid hydroxyamide;  
R-4-[4-(Bromophenoxy)-benzenesulfonyl]-2,2-dimethyl- 1-oxo-thiomorpholine-3-carboxylic  
acid hydroxyamide;  
4-(Ethoxycarbonyl)methyl-1-(4-(4-chlorophenyl)benzenesulfonyl)-N-hydroxy-2R-  
10 piperazinecarboxamide hydrochloride;  
1-Phenethylcarbamoyl-pyrrolidine-2-(R)-carboxylic acid hydroxyamide;  
1-(4-Benzyl-piperazine-1-sulfonyl)-piperidine-2-carboxylic acid hydroxyamide;  
3(S)-N-Hydroxy-4-(4-(pyridin-4-yl) oxybenzenesulfonyl)-2, 2- dimethyl-tetrahydro-2H-1,4-  
thiazine-3-carboxamide;  
15 2(R)-4-Methyl-1-(4-(4-fluorophenyl)benzenesulfonyl)-N-hydroxy-piperazine-2-carboxamide;  
1-((2-Pyridyl)-4-piperazine- 1-sulfonyl)-piperidine-2-carboxylic acid hydroxyamide;  
1-1-[4-(Pyridin-4-ylsulfamyl)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;  
N-(4-Phenoxy-benzenesulfonyl)-D-tert-leucine-N-hydroxyamide;  
2,2-Dimethyl-4-[4-(pyridin-2-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid  
20 hydroxyamide;  
N-1-[4-(4-Fluorophenoxy) benzenesulfonyl]-D-tert-leucine, N-hydroxyamide;  
3(R)-N-Hydroxy-4-(4-(pyridin-4-yl) oxybenzenesulfonyl)-2, 2-dimethyl-tetrahydro-2H-1,4-  
thiazine-3-carboxamide hydrochloride;  
2-[4-(4-Chloro-phenoxy)-benzenesulfonylamino]-N-hydroxy-3,3-dimethyl-butyramide;  
25 3(R)-N-Hydroxy-4-(4-(fur-3-yl) phenoxybenzenesulfonyl)-2, 2- dimethyl-tetrahydro-2H-1,4-  
thiazine-3-carboxamide;  
2-1-[4-(Pyridin-2-yl-oxy)-benzenesulfonylamino]-N-hydroxy-3, 3- dimethyl butyramide;  
2-(2-Biphenyl-4-yl-ethylsulfonyl)-cyclohex-1-ene-carboxylic acid hydroxyamide;  
6-(2-Biphenyl-4-yl-ethyl sulfonyl)-cyclohex-1-ene-carboxylic acid hydroxyamide;  
30 N-(4-Phenoxy-benzenesulfonyl)-3, 3-dimethyl-S-(methylthio)-D- cysteine, N-hydroxyamide;  
1- (4-Phenoxy-piperidine-1-sulfonyl)-piperidine-2-carboxylic acid hydroxyamide;  
N-(4-[4-Chlorophenoxy]-benzenesulfonyl)-3,3-dimethyl-S-(methylthio)-D-cysteine, N-  
hydroxyamide;  
N-(4-[4-Chlorophenoxy]-benzenesulfonyl)-3,3-dimethyl-S-(methylsulfonyl)-D-cysteine, N-  
35 hydroxyamide;  
cis-2-(2-Phenyl-ethanesulfonyl)-cyclohexanecarboxylic acid hydroxyamide;  
3(R)-N-Hydroxy-4-(4-(imidazol-1-yl) phenoxybenzenesulfonyl)-2, 2- dimethyl-tetrahydro-2H-  
1,4-thiazine-3-carboxamide;

3(R)-N-Hydroxy-4-(4-(pyridin-4-yl) oxybenzenesulfonyl)-2, 2- dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide;  
4-1-[2-(2-Hydroxycarbamylmethyl-5-phenyl-pentanoylamino)-4-methyl-pentanoyl]-benzoic acid methyl ester;  
5 trans-2-(2-Phenyl-ethanesulfonyl)-cyclohexanecarboxylic acid hydroxyamide;  
3,3-Dimethyl-2-(4-phenoxy-phenylsulfonylmethyl)-butyric acid, N-hydroxyamide;  
2-(2-Biphenyl-4-yl-ethanesulfonyl)-cyclohexanecarboxylic acid hydroxamate;  
2-[4-(4-Chlorophenyl)-piperazine-1-sulfonylamino]-3-methyl-3-(pyridin-2-ylmethylsulfonyl)-butyric acid N-hydroxyamide;  
10 3,3-Dimethyl-2-(4-phenoxy-phenylsulfonylmethyl)-butyric acid, N-hydroxyamide;  
2(R)-[4-(4-Fluoro-phenoxy) benzenesulfonylamino]-3-methyl-3-(pyridin-2-yl sulfanyl)-butyric acid, hydroxyamide;  
3(R)-N-Hydroxy-4-(4-((pyridin-4-yl) methyl) oxybenzenesulfonyl)--2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide;  
15 1-1-[4-(4-Chloro-phenoxy)-benzenesulfonyl]-4-(1-methyl-1H- imidazole-4-sulfonyl)-piperazine-2-carboxylic acid hydroxamate;  
1-[4-(Pyridin-2-ylsulfanyl)-piperidine- 1-sulfonyl]-piperidine-2- carboxylic acid hydroxyamide;  
2R-[4-(4-Furan-3-yl-phenoxy)-benzenesulfonylamino]-N-hydroxy-3-methyl-3-(pyridin-4-ylsulfanyl)-butyramide;  
20 trans-2-(2-Biphenyl-4-yl-ethylsulfonyl)-cyclohexanecarboxylic acid hydroxyamide;  
N4-(2, 2-Dimethyl-1 S-hydroxymethyl-propyl)-N1-hydroxy-3R [3-(4-pyridin-4-yl-phenyl)-pyrrol-1-yl]-succindiamide;  
1-[4-(4-Fluoro-phenoxy)-benzenesulfonyl]-3,3-dimethyl-5-oxo-piperazine-2-carboxylic acid hydroxyamide;  
25 2(R)-[4-(4-Iodo-phenoxy)benzenesulfonylamino]-3-methyl-(pyridin-3-yl-sulfonyl) butyric acid hydroxyamide;  
1-[2-(Benzothiazol-2-ylsulfanyl)-piperidine-1-sulfonyl]-piperidine-2-carboxylic acid hydroxyamide;  
5-[4-(4-Fluoro-phenoxy)-benzenesulfonyl]-4, 5, 6, 7-tetrahydro-3H-Imidazolo[4,5,-c]pyridine-6-  
30 carboxylic acid hydroxyamide;  
1-[4-(Pyridin-4-ylsulfanyl)-piperidine- 1-sulfonyl]-piperidine-2carboxylic acid hydroxyamide;  
1-[4-(4-Methoxy-phenylsulfamyl)-piperidine-1-sulfonyl]piperidine-2-carboxylic acid hydroxyamide;  
2(R)-[4-(4-Methylphenoxy)benzenesulfonylamino]-3-methyl-3-(pyridin-3-yl-sulfonyl) butyric  
35 acid hydroxyamide;  
1-[4-(4-Methyl-phenylsulfamyl)-piperidine-1-sulfonyl]-piperidine- 2-carboxylic acid hydroxamate;  
4-Methoxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide;

4-1-[4-(4-Chloro-phenoxy)-benzenesulfonyl]-2, 2-dimethyl- thiomorpholine-3-carboxylic acid hydroxyamide;

2 (R)-[4-(4-bromo-phenoxy) benzenesulfonylamino]-3-methyl-3-(pyridin-4-yl-sulfoxide) butyric acid hydroxyamide;

, 5 4-(4-Methoxy-benzenesulfonyl)-2,2-dimethyl-1-oxo-thiomorpholine-3-carboxylic acid hydroxyamide;

4-4-(4-Chloro-phenoxy)-benzenesulfonyl]-2, 2-dimethoxy-1-oxo-thiomorpholine-3-carboxylic acid hydroxyamide;

3 (S)-2, 2-Dimethyl-4-[4-(pyridin-4-ylsulfanyl)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide;

10 3, 3-Dimethyl-N-hydroxy-2R-[4-(pyridin-4-ylsulfanyl)-piperidine- 1-sulfonylamino]-butyramide;

N-Hydroxy-2-[-(4-methylbenzenesulfonyl) amino] acetamide;

[4-(4-Imidazol-1-yl-phenoxy)-piperidine-1-sulfonyl]-piperidine- 2-carboxylic acid

15 hydroxyamide;

1-[4-(4-Imidazol-1-yl-phenylsulfanyl)-piperidine-1-sulfonyl]-piperidine-2-carboxylic acid hydroxyamide;

2(R)-[4-(4-Chloro-benzoyl)-cyclohexanesulfonyl]-piperidine-1- carboxylic acid hydroxyamide;

1(R)-[4-(4-Chloro-benzoyl)-piperidine-1-sulfonyl]-piperidine-2- carboxylic acid hydroxyamide;

20 1(R)-(4-Pyridin-2-yl-piperazine-1-sulfonyl)-piperidine-2- carboxylic acid hydroxyamide;

1(R)-[4-(4-Imidazol-1-yl-phenoxy)-piperidine-1-sulfonyl]- piperidine-2-carboxylic acid hydroxyamide;

N-Hydroxy-3,3-dimethyl-2R-[4-(morpholine-4-carbonyl)-piperidine-1-sulfonylamino]-butyramide;

25 N-Hydroxy-3-methyl-3-(5-methyl-isoxazol-3-yl-methylsulfanyl)- 2R-[4-(pyridin-4-ylsulfanyl)-piperidine-sulfonylamino]-butyramide;

N-Hydroxy-2R-[4-(4-Imidazol-1-yl-phenoxy)-piperidine- 1-sulfonylamino]-3,3-dimethyl-butyramide;


30 2R-[4-(4-Chloro-benzoyl)-piperazine-1-sulfonylamino]-N-hydroxy-3-methyl-3-methylsulfanyl-butyramide;

N-Hydroxy-3-methyl-3-methylsulfanyl-2R-[4-(pyridin-4-ylsulfanyl)-piperidine-1-sulfonylamino]-butyramide;


1R,3S,2,2-Dimethyl-1-oxo-4-[4-(pyridin-4-ylsulfanyl)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide; and the pharmaceutically acceptable salts thereof.

35 In yet another embodiment of the present invention, the hydroxamate MMP inhibitors are selected from the group consisting of:

10




11



the pharmaceutically acceptable salts thereof.

5 In yet another embodiment of the present invention, the hydroxamate MMP inhibitors have the formula:



wherein:

10 Q is a divalent radical having four ring atoms which together with C\* and N form a six-membered ring, where each of said four ring atoms independently is unsubstituted or substituted by a suitable substituent, and at least one of said four ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; Ar is an aryl or heteroaryl group;  
 or the pharmaceutically acceptable salts thereof, see U.S. Patent No. 5,753,653, incorporated herein in its entirety by reference.


15 In yet another embodiment of the present invention, the hydroxamate MMP inhibitors are selected from the group consisting of:

20 2(R)-N-hydroxy-1-(4-(4-chlorophenoxy) benzenesulfonyl)-4-(methanesulfonyl)-piperazine-2-carboxamide;  
 20 2(R)-N-hydroxy-1-(4-(4-fluorophenoxy) benzenesulfonyl)-4-(methanesulfonyl)-piperazine-2-carboxamide;

3(S)-N-hydroxy-4-((4-((pyrid-4-yl) oxy)benzenesulfonyl)-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide;

and the pharmaceutically acceptable salts thereof.

In yet another embodiment of the present invention, the hydroxamate MMP Inhibitors 5 have the formula:



wherein Y is O or S;

Ar is an aryl group or a heteroaryl group;

R is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a 10 heteroaryl group, or -C(O)R1,

wherein R1 is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or NR2 R3, wherein R2 and R3 independently are hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group; or the pharmaceutically acceptable salts thereof, see U.S. Patent No. 5,985,900, incorporated 15 herein in its entirety by reference.

In yet another embodiment of the present invention, the hydroxamate MMP inhibitors are selected from the group consisting of:

- 2(S)-N-hydroxy-3,3-dimethyl-2-[(4-(4-fluorophenoxy)benzenesulfonyl)-amino]butanamide;
- 2(S)-N-hydroxy-3,3-dimethyl-2-[(4-(4-chlorophenoxy)benzenesulfonyl)-amino]butanamide;
- 20 2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-fluorophenoxy)benzenesulfonyl)-amino]butanamide;
- 2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-bromophenoxy)benzenesulfonyl)-amino]butanamide;
- 25 2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-iodophenoxy)benzenesulfonyl)-amino]butanamide;
- 2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-(4-fluorophenoxy)benzenesulfonyl)-amino]butanamide;
- 30 2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-(4-bromophenoxy)benzenesulfonyl)-amino]butanamide;
- 2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-methylphenoxy)benzenesulfonyl)-amino]butanamide;
- 2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-(pyrid-4-yloxy)benzenesulfonyl)-amino]butanamide;

2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-((pyrid-4-yl)sulfanyl)-benzenesulfonyl)amino]butanamide;

2(S)-N-hydroxy-3-methyl-3-(1H-imidazol-4-yl)methylsulfanyl-2-[(4-(4-bromophenoxy)benzenesulfonyl)-amino]butanamide;

5 2(S)-N-hydroxy-3-methyl-3-(1-methyl-1H-imidazol-2-yl) methylsulfanyl-2-[(4-(4-bromophenoxy)-benzenesulfonyl)amino]butanamide;


2(S)-N-hydroxy-3-methyl-3-(1-methyl-1H-imidazol-4-yl) methylsulfanyl-2-[(4-(4-bromophenoxy)-benzenesulfonyl)amino]butanamide;


10 2(S)-N-hydroxy-3-methyl-3-(4-methyl-4H-[1,2,4]-triazol-3-yl) methylsulfanyl-2-[(4-(4-bromophenoxy)-benzenesulfonyl)amino]butanamide;

2(S)-N-hydroxy-3-methyl-3-(1-methyl-4H-[1,2,4]-triazol-3-yl) methylsulfanyl-2-[(4-(4-bromophenoxy)-benzenesulfonyl)amino]butanamide;

15 2(S)-N-hydroxy-3-methyl-3-methylsulfanyl-2-[(4-(4-chlorophenoxy)benzenesulfonyl)amino]butanamide; and the pharmaceutically acceptable salts thereof.

In a preferred embodiment of the present invention, the hydroxamate MMP inhibitors are selected from the group consisting of:





5

Detailed Description of The Invention And Preferred Embodiments

For purposes of the present invention, as described and claimed herein, the following terms are defined as follows:

As used herein, the terms "comprising" and "including" are used in their open, non-limiting sense.

The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched, or cyclic moieties (including fused and bridged bicyclic and spirocyclic moieties), or a combination of the foregoing moieties. For an alkyl group to have cyclic moieties, the group must have at least three carbon atoms.

A "lower alkyl" is intended to mean an alkyl group having from 1 to 4 carbon atoms in its chain. The term "heteroalkyl" refers to a straight- or branched-chain alkyl group having from 2 to 12 atoms in the chain, one or more of which is a heteroatom selected from S, O, and N. Exemplary heteroalkyls include alkyl ethers, secondary and tertiary amines, alkyl sulfides and the like.

The term "alkenyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above and including E and Z isomers of said alkenyl moiety.

The term "alkynyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above.

The term "carbocycle" refers to a saturated, partially saturated, unsaturated, or aromatic, monocyclic or fused or non-fused polycyclic, ring structure having only carbon ring

atoms (no heteroatoms, i.e., non-carbon ring atoms). Exemplary carbocycles include cycloalkyl, aryl, and cycloalkyl-aryl groups.

The term "heterocycle" refers to a saturated, partially saturated, unsaturated, or aromatic, monocyclic or fused or non-fused polycyclic, ring structure having one or more heteroatoms selected from N, O, and S. Exemplary heterocycles include heterocycloalkyl, heteroaryl, and heterocycloalkyl-heteroaryl groups.

A "cycloalkyl group" is intended to mean a saturated or partially saturated, monocyclic, or fused or spiro polycyclic, ring structure having a total of from 3 to 18 carbon ring atoms (but no heteroatoms). Exemplary cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptyl, adamantyl, and like groups.

A "heterocycloalkyl group" is intended to mean a monocyclic, or fused or spiro polycyclic, ring structure that is saturated or partially saturated, and has a total of from 3 to 18 ring atoms, including 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur. Illustrative Examples of heterocycloalkyl groups include pyrrolidinyl, tetrahydrofuryl, 15 piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl, and like groups.

The term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.

The term "4-10 membered heterocyclic", as used herein, unless otherwise indicated, includes aromatic and non-aromatic heterocyclic groups containing one to four heteroatoms each selected from O, S and N, wherein each heterocyclic group has from 4-10 atoms in its ring system, and with the proviso that the ring of said group does not contain two adjacent O or S atoms. Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system. The heterocyclic groups include benzo-fused ring systems. An example of a 4 membered heterocyclic group is azetidinyl (derived from azetidine). An example of a 5 membered heterocyclic group is thiazolyl and an example of a 10 membered heterocyclic group is quinoliny. Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuryl, dihydrofuryl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, 20 homopiperidinyl, oxepanyl, thlepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuryl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-Indolyl and quinolizinyl. Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thieryl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, 30 35

benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. The foregoing groups, as derived from the groups listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole 5 may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached). An example of a heterocyclic group wherein 2 ring carbon atoms are substituted with oxo (=O) moieties is 1,1-dioxothiomorpholinyl.

A "heteroaryl group" is intended to mean a monocyclic or fused or spiro polycyclic, aromatic ring structure having from 4 to 18 ring atoms, including from 1 to 5 heteroatoms 10 selected from nitrogen, oxygen, and sulfur. Illustrative Examples of heteroaryl groups include pyrrolyl, thienyl, oxazolyl, pyrazolyl, thiazolyl, furyl, pyridinyl, pyrazinyl, triazolyl, tetrazolyl, indolyl, quinoliny, quinoxalinyl, benzthiazolyl, benzodioxinyl, benzodioxolyl, benzooxazolyl, and the like.

The term "alkoxy", as used herein, unless otherwise indicated, includes O-alkyl groups wherein 15 alkyl is as defined above.

The term "amino" is intended to mean the  $-\text{NH}_2$  radical.

The term "halogen" represents chlorine, fluorine, bromine or iodine.

The term "halo", as used herein, unless otherwise indicated, means fluoro, chloro, bromo or iodo. Preferred halo groups are fluoro, chloro and bromo.

20 The term "a pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness of the free acids and bases of the specified compound and that is not biologically or otherwise undesirable. A compound of the invention may possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. Exemplary pharmaceutically acceptable salts include those 25 salts prepared by reaction of the compounds of the present invention with a mineral or organic acid or an inorganic base, such as salts including sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrate, citrates, lactates,  $\gamma$ -hydroxybutyrate, glycollates, tartrates, methane-sulfonates, propanesulfonates, 30 naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.

The term "substituted" means that the specified group or moiety bears one or more substituents. The term "unsubstituted" means that the specified group bears no substituents. The term "optionally substituted" means that the specified group is unsubstituted or substituted by one or more substituents.

5 The term "HCV-inhibiting agent" means any hydroxamate MMP inhibitor or hydroxamate compound represented by formula I or a pharmaceutically acceptable salt, hydrate, prodrug, active metabolite or solvate thereof.

The term "hydroxamate MMP inhibitor" refers to any MMP inhibitor containing a "-NH-OH". Examples of hydroxamate MMP inhibitors can be found in, but not limited to, PCT 10 Publication No. WO 00/04892 to Bocan; U.S. Patent No. 5,985,900 to Bender et. al., and U.S. Patent No. 5753,653 to Bender et. al., each of which is incorporated herein in their entirety by reference.

The term "hydroxamate compound" refers to any compounds containing a "-NH-OH".

The term "processes mediated by HCV polymerase", as used herein, refers to 15 biological, physiological, endocrinological, and other bodily processes which are mediated by receptor or receptor combinations which are responsive to the hydroxamate MMP inhibitors described herein (e.g., hepatitis C or chronic liver disease, including cirrhosis and hepatocellular carcinoma (Hoofnagle, J. H.; 1997; Hepatology 26: 15S-20S, incorporated herein by reference), the formation of macrophages which lead to the development of 20 atherosclerotic plaques, and the like). Modulation of such processes can be accomplished in vitro or in vivo. In vivo modulation can be carried out in a wide range of subjects, such as, for example, humans, rodents, sheep, pigs, cows, and the like.

The term "interfering with or preventing" HCV viral replication in a cell means to 25 reduce HCV replication or production of HCV components necessary for progeny virus in a cell as compared to a cell not being transiently or stably transduced with the ribozyme or a vector encoding the ribozyme. Simple and convenient assays to determine if HCV viral replication has been reduced include an ELISA assay for the presence, absence, or reduced presence of anti-HCV antibodies in the blood of the subject (Nasoff et al., PNAS 88:5462-5466, 1991), RT-PCR (Yu et al., In Viral Hepatitis and Liver Disease 574-477, Nishioka, 30 Suzuki and Mishiro (Eds.); Springer-Verlag Tokyo, 1994) or liver function tests. Such methods are well known to those of ordinary skill in the art. Alternatively, total RNA from transduced and infected "control" cells can be isolated and subjected to analysis by dot blot or northern blot and probed with HCV specific DNA to determine if HCV replication is reduced. Alternatively, reduction of HCV protein expression can also be used as an indicator of 35 inhibition of HCV replication. A greater than fifty percent reduction in HCV replication as compared to control cells typically quantitates a prevention of HCV replication.

The term "pharmaceutically acceptable carrier" refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, and which does

not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.

The term "prodrug" is a compound that may be converted under physiological conditions or by solvolysis to the specified compound or to a pharmaceutically acceptable salt of such compound. A prodrug may be a derivative of one of the hydroxamate compounds of the present invention that contains a moiety, such as for example -CO<sub>2</sub>R, -PO(OR)<sub>2</sub> or -C=NR, that may be cleaved under physiological conditions or by solvolysis. Any suitable R substituent may be used that provides a pharmaceutically acceptable solvolysis or cleavage product. A prodrug containing such a moiety may be prepared according to conventional procedures by treatment of a hydroxamate compound of this invention containing, for example, an amido, carboxylic acid, or hydroxyl moiety with a suitable reagent.

The term "active metabolite" refers to a pharmacologically active product produced through metabolism in the body of a specified hydroxamate compound or salt thereof.

Prodrugs and active metabolites of the hydroxamate compound may be identified using routine techniques known in the art. See, e.g., Bertolini et al., *J. Med. Chem.*, 40:2011-2016 (1997); Shan et al., *J. Pharm. Sci.*, 86 (7):765-767 (1997); Bagshawe, *Drug Dev. Res.*, 34:220-230 (1995); Bodor, *Advances in Drug Res.*, 13:224-331 (1984); Bundgaard, "Design of Prodrugs" (Elsevier Press, 1985); Larsen, *Design and Application of Prodrugs*, Drug Design and Development (Krosgaard-Larsen et al. eds., Harwood Academic Publishers, 1991); Dear et al., *Chromatogr. B*, 748:281-293 (2000); Spraul et al., *J. Pharmaceutical & Biomedical Analysis*, 10 (8):601-605 (1992); and Prox et al., *Xenobiotol*, 3(2):103-112 (1992).

The term "solvate" is intended to mean a pharmaceutically acceptable solvate form of a specified compound that retains the biological effectiveness of such compound. Examples of solvates include compounds of the invention in combination with water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.

If a hydroxamate compound used in the method of the invention is a base, a desired salt may be prepared by any suitable method known to the art, including treatment of the free base with an inorganic acid (such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like), or with an organic acid (such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acid (such as glucuronic acid or galacturonic acid), alpha-hydroxy acid (such as citric acid or tartaric acid), amino acid (such as aspartic acid or glutamic acid), aromatic acid (such as benzoic acid or cinnamic acid), sulfonic acid (such as p-toluenesulfonic acid or ethanesulfonic acid), and the like.

If a hydroxamate compound used in the method of the invention is an acid, a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base (such as an amine (primary, secondary, or tertiary)), an alkali metal hydroxide, or alkaline earth metal hydroxide. Illustrative examples of suitable

salts include organic salts derived from amino acids (such as glycine and arginine), ammonia, primary amines, secondary amines, tertiary amines, and cyclic amines (such as piperidine, morpholine, and piperazine), as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.

5 In the case of hydroxamate compound, prodrugs, salts, or solvates that are solids, it is understood by those skilled in the art that the hydroxamate compound, prodrugs, salts, and solvates used in the method of the invention, may exist in different polymorph or crystal forms, all of which are intended to be within the scope of the present invention and specified formulas. In addition, the hydroxamate compound, salts, prodrugs and solvates used in the  
10 method of the invention may exist as tautomers, all of which are intended to be within the broad scope of the present invention.

15 In some cases, the hydroxamate compound, salts, prodrugs and solvates used in the method of the invention may have chiral centers. When chiral centers are present, the hydroxamate compound, salts, prodrugs and solvates may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates, and mixtures thereof are intended to be within the broad scope of the present invention.

20 As generally understood by those skilled in the art, an optically pure compound is one that is enantiomerically pure. As used herein, the term "optically pure" is intended to mean a compound comprising at least a sufficient activity. Preferably, an optically pure amount of a single enantiomer to yield a compound having the desired pharmacological pure compound of the invention comprises at least 90% of a single isomer (80% enantiomeric excess), more preferably at least 95% (90% e.e.), even more preferably at least 97.5% (95% e.e.), and most preferably at least 99% (98% e.e.).

25 The term "treating", as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above.

30 The activity of the hydroxamate compound as inhibitors of HCV activity may be measured by any of the suitable methods available in the art, including *in vivo* and *in vitro* assays. An Example of a suitable assay for activity measurements is the HCV replicon assay described herein.

35 Administration of the hydroxamate compound and their pharmaceutically acceptable prodrugs, salts, active metabolites, and solvates may be performed according to any of the accepted modes of administration available to those skilled in the art. Illustrative Examples of suitable modes of administration include oral, nasal, parenteral, topical, transdermal, and rectal. Oral and intravenous deliveries are preferred.

An HCV-inhibiting agent may be administered as a pharmaceutical composition in any suitable pharmaceutical form. Suitable pharmaceutical forms include solid, semisolid, liquid, or lyophilized formulations, such as tablets, powders, capsules, suppositories, suspensions, liposomes, and aerosols. The HCV-inhibiting agent may be prepared as a 5 solution using any of a variety of methodologies. For Example, the HCV-inhibiting agent can be dissolved with acid (e.g., 1 M HCl) and diluted with a sufficient volume of a solution of 5% dextrose in water (D5W) to yield the desired final concentration of HCV-inhibiting agent (e.g., about 15 mM). Alternatively, a solution of D5W containing about 15 mM HCl can be used to provide a solution of the HCV-inhibiting agent at the appropriate concentration. Further, the 10 HCV-inhibiting agent can be prepared as a suspension using, for example, a 1% solution of carboxymethylcellulose (CMC).

Acceptable methods of preparing suitable pharmaceutical forms of the pharmaceutical compositions are known or may be routinely determined by those skilled in the art. For Example, pharmaceutical preparations may be prepared following conventional 15 techniques of the pharmaceutical chemist involving steps such as mixing, granulating, and compressing when necessary for tablet forms, or mixing, filling, and dissolving the ingredients as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraaural, and/or rectal administration.

Pharmaceutical compositions of the invention may also include suitable excipients, 20 diluents, vehicles, and carriers, as well as other pharmaceutically active agents, depending upon the intended use. Solid or liquid pharmaceutically acceptable carriers, diluents, vehicles, or excipients may be employed in the pharmaceutical compositions. Illustrative solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, pectin, acacia, magnesium stearate, and stearic acid. Illustrative liquid carriers include syrup, peanut oil, olive oil, saline solution, and water. The carrier or diluent may include a suitable prolonged-release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. When a liquid carrier is used, the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g., solution), or a nonaqueous or aqueous liquid suspension.

30 A dose of the pharmaceutical composition may contain at least a therapeutically effective amount of an HCV-inhibiting agent and preferably is made up of one or more pharmaceutical dosage units. The selected dose may be administered to a mammal, for example, a human patient, in need of treatment mediated by inhibition of HCV activity, by any known or suitable method of administering the dose, including topically, for example, as an ointment or cream; orally; rectally, for example, as a suppository; parenterally by injection; 35 intravenously; or continuously by intravaginal, intranasal, intrabronchial, intraaural, or intraocular infusion. When the composition is administered in conjunction with a cytotoxic drug, the composition can be administered before, with, and/or after introduction of the

cytotoxic drug. However, when the composition is administered in conjunction with radiotherapy, the composition is preferably introduced before radiotherapy is commenced.

The phrases "therapeutically effective amount" and "effective amount" are intended to mean the amount of an inventive agent that, when administered to a mammal in need of treatment, is sufficient to effect treatment for injury or disease conditions alleviated by the inhibition of HCV viral replication such as for potentiation of anti-cancer therapies or inhibition of neurotoxicity consequent to stroke, head trauma, and neurodegenerative diseases. The amount of a given HCV-inhibiting agent used in the method of the invention that will be therapeutically effective will vary depending upon factors such as the particular HCV-inhibiting agent, the disease condition and the severity thereof, the identity and characteristics of the mammal in need thereof, which amount may be routinely determined by artisans.

It will be appreciated that the actual dosages of the HCV-inhibiting agents used in the pharmaceutical compositions of this invention will be selected according to the properties of the particular agent being used, the particular composition formulated, the mode of administration and the particular site, and the host and condition being treated. Optimal dosages for a given set of conditions can be ascertained by those skilled in the art using conventional dosage-determination tests. For oral administration, e.g., a dose that may be employed is from about 0.001 to about 1000 mg/kg body weight, preferably from about 0.1 to about 100 mg/kg body weight, and even more preferably from about 1 to about 50 mg/kg body weight, with courses of treatment repeated at appropriate intervals.

#### EXAMPLES

In the examples described below, unless otherwise indicated, all temperatures are set forth in degrees Celsius and all parts and percentages are by weight. Reagents were purchased from commercial suppliers, such as Sigma-Aldrich Chemical Company, or Lancaster Synthesis Ltd. and were used without further purification unless otherwise indicated. Tetrahydrofuran (THF) and N, N-dimethylformamide (DMF) were purchased from Aldrich in Sure Seal bottles and used as received. All solvents were purified using standard methods known to those skilled in the art, unless otherwise indicated.

The reactions set forth below were done generally under a positive pressure of argon at an ambient temperature (unless otherwise stated) in anhydrous solvents, and the reaction flasks were fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried. Analytical thin layer chromatography (TLC) was performed on glass-backed silica gel 60 F 254 plates from Analtech (0.25 mm), eluted with the appropriate solvent ratios (v/v), and are denoted where appropriate. The reactions were assayed by TLC, HPLC, or <sup>1</sup>H NMR, and terminated as judged by the consumption of starting material.

Visualization of the TLC plates was done with iodine vapor, ultraviolet illumination, 2% Ce(NH<sub>4</sub>)<sub>2</sub>(SO<sub>4</sub>)<sub>2</sub> in 20% aqueous sulfuric acid, 2% ninhydrin in ethanol, or p-anisaldehyde spray reagent, and activated with heat where appropriate. Work-ups were typically done by doubling the reaction volume with the reaction solvent or extraction solvent and then washing 5 with the indicated aqueous solutions using 25% by volume of the extraction volume unless otherwise indicated. Product solutions were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and/or MgSO<sub>4</sub> prior to filtration and evaporation of the solvents under reduced pressure on a rotary evaporator and noted as solvents removed in vacuo. Flash column chromatography (Still et al., *J. Org. Chem.*, 1978, 43, 2923-2924) was done using Merck silica gel (47-61 µm) with a 10 silica gel crude material ratio of about 20:1 to 50:1, unless otherwise stated. Certain example compounds were purified via preparative high-performance liquid chromatography (HPLC), and unless otherwise indicated, refers to a Gilson 321 system, equipped with a C18 reversed-phase preparative column (Metasil AQ 10 micron, 120A, 250 × 21.2 mm, MetaChem) and elution with a gradient of 0.1% trifluoroacetic acid (TFA)/5% acetonitrile/water to 0.1% 15 TFA/5% water/acetonitrile over 20 min and flow rate of 20 mL/min. Hydrogenations were performed at ambient pressure unless otherwise indicated. All melting points (mp) are uncorrected.

<sup>1</sup>H-NMR spectra were recorded on a Bruker or Varian instrument operating at 300 MHz and <sup>13</sup>C-NMR spectra were recorded operating at 75 MHz. NMR spectra were obtained 20 as CDCl<sub>3</sub> solutions (reported in ppm), using chloroform as the reference standard (7.27 ppm and 77.00 ppm) unless otherwise indicated. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broad singlet), bm (broad multiplet), dd (doublet of doublets), ddd (doublet of doublet of doublets), dddd (doublet of doublet of doublet of doublets), dt (doublet of triplets). Coupling 25 constants, when given, are reported in Hertz (Hz).


Infrared (IR) spectra were recorded on a Perkin-Elmer FT-IR Spectrometer as neat oils, KBr pellets, or CDCl<sub>3</sub> solutions, and when given are reported in wave numbers (cm<sup>-1</sup>). Mass spectrometry was conducted with various techniques. Matrix-Assisted Laser Desorption/Ionization Fourier Transform Mass Spectrometry (MALDI FTMS), was performed 30 on an IonSpec FTMS mass spectrometer. Samples are irradiated with a nitrogen laser (Laser Science Inc.) operated at 337nm and the laser beam is attenuated by a variable attenuator and focused on the sample target. The ions are then differentiated according to their m/z using an ion cyclotron resonance mass analyzer. The electrospray ionization (ESI) mass spectrometry experiments were performed on an API 100 Perkin Elmer SCIEX single 35 quadrupole mass spectrometer. Electrospray samples are typically introduced into the mass analyzer at a rate of 4.0 µl/minute. The positive and negative ions, generated by charged droplet evaporation, enter the analyzer through an interface plate and a 100 mm orifice, while

the declustering potential is maintained between 50 and 200V to control the collisional energy of the ions entering the mass analyzer. The emitter voltage is typically maintained at 4000V. The liquid chromatography (LC) electrospray ionization (ESI) mass spectrometry experiments were performed on an Hewlett-Packard (HP) 1100 MSD single quadrupole mass spectrometer. Electrospray samples are typically introduced into the mass analyzer at a rate of 100 to 1000  $\mu$ l/minute. The positive and negative ions, generated by charged droplet evaporation, enter the analyzer through a heated capillary plate, while the declustering potential is maintained between 100 and 300V to control the collisional energy of the ions entering the mass analyzer. The emitter voltage is typically maintained at 4000V.

10 Hydroxamate MMP Inhibitors as used in the method of the present invention can be prepared as described in PCT Publication No. WO 00/04892 to Bocan; U.S. Patent No. 5,985,900 to Bender et. al., and U.S. Patent No. 5753,653 to Bender et. al., each of which is incorporated herein in their entirety by reference.

15 Preferred compounds in accordance with the invention may be prepared in manners analogous to those specifically described below.

**Example 1: 2-(2-Biphenyl-4-yl-ethylsulfonyl)-cyclohex-1-ene-carboxylic Acid Hydroxyamide**



A solution of compound 1a (0.066 g, 0.11 mmol), 1N N,N,N,N-tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF; 22 mL, 22 mmol) and THF (1 mL) stirred at ambient temperature for 25 minutes. To the solution was added ethyl acetate (30 mL), then the solution was washed with H<sub>2</sub>O (3 x 20 mL), brine (20 mL), dried, and evaporated to give an oil, 0.065 g. The crude product was purified by column chromatography (stepwise gradient 20% ethyl acetate/hexane-100%ethyl acetate) and crystallized from some fractions to give a white solid (4 mg, 10% yield).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.59-7.14 (9H, m), 3.07-2.83 (4H, m), 2.36 (1H, m), 1.65-1.50 (7H, m).

HRFABMS Calcd for C<sub>21</sub>H<sub>23</sub>O<sub>2</sub>Sn: 376.1347. Found 376.1358.

10 **Preparation of compound 1a: 2-(2-Biphenyl-4-yl-ethylsulfanyl)-cyclohex-1-ene-carboxylic Acid (O-tert-Butylidiphenylsilyl) Hydroxyamide**

A solution of compound 1b (247 mg, 0.730 mmol), O-dimethyl-tert-butylsilyl hydroxylamine (299 mg, 1.10 mmol, 1.5 eq), and 1-[3-(dimethylamino)-propyl]-3-ethylcarbodiimide hydrochloride (EDC; 280 mg, 1.46 mmol, 2.00 eq) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) stirred at ambient temperature for 18 hours. Added CH<sub>2</sub>Cl<sub>2</sub> (30 mL), washed with H<sub>2</sub>O (40 mL), dried, and evaporated to give a crude product (0.3 g), which was purified by column chromatography (CH<sub>2</sub>Cl<sub>2</sub>) to give 0.19 g (44%) of a solid, which was used without further purification.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.45 (1H, bs), 8.75-7.15 (20H, m), 2.90 (2H, m), 2.65 (2H, m), 2.15 (2H, m), 1.45 (4H, m), 1.10 (2H, m).

20 **Preparation of compound 1b: 2-(2-Biphenyl-4-yl-ethylsulfanyl)-cyclohex-1-ene-carboxylic Acid.**

The crude mixture of compounds 1c and 1d (1.81 g; 4.94 mmol), 1N KOH (20 mL, 4 eq), and ethanol (15 mL) was heated at reflux for 5 hours, allowed to cool, and evaporated.

The resultant residue was treated with water (30 mL), washed with ethyl acetate (3 x 30 mL), acidified with 6N HCl, and extracted with ethyl acetate (2 x 30 mL). The acidified, latter organic extracts were washed with brine (30 mL) and concentrated in vacuo. The specific titular isomer was isolated by crystallization from ethanol/hexanes. The mother liquor also provided the other possible isomer 6-(2-biphenyl-4-yl-ethylsulfanyl)-cyclohex-1-ene-carboxylic acid, see Example 2 below.

30 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): δ 12.14 (1H, bs), 7.67-7.60 (9H, m), 4.10 (2H, s), 2.54 (2H, s), 2.24 (2H, s), 1.60-1.53 (4H, m). Anal. For C<sub>20</sub>H<sub>20</sub>OS: C, 74.04, H, 6.21; S, 9.88. Found C, 73.81, H, 6.26, S, 9.78.

35 **Preparation of compounds 1c and 1d: 2-(2-Biphenyl-4-yl-ethylsulfanyl)-cyclohex-1-ene-carboxylic Acid Ethyl Ester and 6-(2-Biphenyl-4-yl-ethylsulfanyl)-cyclohex-1-ene-carboxylic Acid Ethyl Ester**

A mixture of compound 1e (630 mg, 2.94 mmol), 2-oxo-cyclohexane-carboxylic acid ethyl ester (500 mg, 2.94 mmol), and Montmorillonite K10 (0.6 g) in toluene (30 mL) was

heated at reflux for 4.5 h. Allowed to cool, filtered, and solvent evaporated to give a light-yellow oil (873 mg, 81%), which was a mixture of isomers by NMR and used without further purification.

**Preparation of compound 1e: 2-Biphenyl-4-yl-ethane-thiol.**

5 A solution of compound 1f (1.5 g, 3.15 mmol) and thiourea (0.62 g, 8.1 mmol, 1.1 eq) in dioxane (15 mL) was heated at reflux for 1 hour. After cooling, the white isothiouronium chloride was filtered off, suspended in 20% NaOH (40 mL) and heated at reflux for 4.5 hours. Allowed to cool, added H<sub>2</sub>O (40 mL) and refluxed for an additional 2 hours. The mixture was then filtered, acidified, poured into H<sub>2</sub>O (100 mL) and extracted with ethyl acetate (2 x 50 mL).

10 The organic layers were combined, dried, and evaporated to give a crude solid which was recrystallized from hexane to give white plates (446 mg, 66%), which was used without further purification.

**Preparation of compound 1f: 4-(2-Bromo-ethyl)-biphenyl (48).**

15 A solution of compound 1g (4.38 g, 22.1 mmol), and CBr<sub>4</sub> (8.79g, 26.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (40 mL) was cooled to 0°C, treated with PPh<sub>3</sub> (8.69 g, 33.1 mmol), and stirred for 0.5h. The solvent was removed, diluted with diethyl ether (100 mL), and filtered. The extract was concentrated and purified by column chromatography (1:1 ethyl acetate/hexane) to give a yellow oil in quantitative yield, which displayed an NMR that matched literature (Kawasaki, M.; Goto, M.; Kawabata, S.; Kometani, T. *Tetrahedron: Asymmetry* 2001, 12, 585-596) and

20 was used without further purification.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.60-7.26 (9H, m), 3.61 (2H, t, J=7.7 Hz), 3.21 (2H, t, J=7.7 Hz).


**Preparation of compound 1g: 2-Biphenyl-4-yl-ethanol.**

25 A solution of 4-biphenylacetic acid (10.61 g, 50.00 mmol, 1 eq) in THF (100 mL) was added dropwise over a 30 min to a slurry of LiAlH<sub>4</sub> (4.74g, 125 mmol) in THF (80 mL) at 0°C. The resultant mixture was heated at reflux for 1.5 hours, re-cooled, carefully quenched with 6N HCl (200 mL), and extracted with diethyl ether (200 mL). The organic layer was washed with H<sub>2</sub>O (300 mL), brine (300 mL), and concentrated to give a solid, which was crystallized from toluene/hexanes to give a cream-colored solid (7.68 g, 78%), which displayed an NMR that matched literature (Kawasaki, M.; Goto, M.; Kawabata, S.; Kometani, T. *Tetrahedron: Asymmetry* 2001, 12, 585-596) and was used without further purification.

30

**Example 2: 6-(2-Biphenyl-4-yl-ethylsulfanyl)-cyclohex-1-ene-carboxylic Acid**

**Hydroxyamide.**



Compound of example 2 was prepared in the same manner as example 1, from compound 2a, as a cream-colored solid after recrystallization from ethanol/hexanes (28%).

5 mp 166-168°C.

$^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  10.51 (1H, s), 8.83 (1H, s), 7.63-7.29 (9H, m), 5.78 (1H, s), 3.88 (2H, s), 3.30 (1H, s), 2.86 (1H, s), 1.95 (2H, bs), 1.70 (3H, m), 1.35 (1H, m). HRFABMS Calcd for  $C_{20}H_{20}NO_2S$ : 340.1371, found 340.1364.

Anal Calcd for  $C_{20}H_{20}NO_2S$ : C, 70.77; H, 6.24, N, 4.13, S, 9.44. Found C, 70.64; H, 6.24; N, 4.1S; S, 9.54.

**Preparation of compound 2a: 6-(2-Biphenyl-4-yl-ethylsulfanyl)-cyclohex-1-ene-carboxylic Acid (O-Dimethyl-tert-butylsilyl)-hydroxyamide.**

Obtained in the same fashion as compound 1a in Example 1, from compound 1b, as a white solid in 8% yield after column chromatography (30%ethyl acetate/hexane): mp 135-137°C.


$^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  10.32 (1H, s), 8.77 (1H, s), 7.63-7.29 (9H, m), 3.96 (2H, s), 2.22 (2H, s), 2.13 (2H, s), 1.51 (4H, bs). HRFABMS Calcd for  $C_{20}H_{22}O_2S$ : 340.1371, found 340.1365.

**Preparation of compound 1d: 6-(2-Biphenyl-4-yl-ethylsulfanyl)-cyclohex-1-ene-carboxylic Acid.**

20 Isolated upon concentration of the mother liquor from the crystallization of compounds 1c and 1d in Example 1 and purification of the oily residue by column chromatography (ethyl acetate) to give an oil (23% yield).

$^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  12.30 (1H, s), 7.67-7.32 (9H, m), 5.84 (1H, s), 3.96 (2H, s), 3.34 (1H, bs), 2.00(2H,bs), 1.85 (2H, m), 1.50 (2H, m). Anal. Calcd for  $C_{20}H_{20}O_2S$ : C, 74.04; H, 6.21, S, 9.88. Found C, 74.15; H, 6.77, S, 9.17.

**Example 3: cis-Phenethylsulfanyl-cyclohexanecarboxylic Acid Hydroxyamide.**



Prepared as described in Example 1, from compound 3a. Recrystallization from diethyl ether/hexanes gave a white solid (0.061 g, 44%).

5 **Preparation of compound 3a: cis-Phenethylsulfanyl-cyclohexanecarboxylic Acid (O-Dimethyl-tert-butylsilyl)-hydroxylamide.**

Prepared as described for compound 1a in Example 1, from compound 3b. Purification by column chromatography (20% ethyl acetate/hexanes) gave a white solid (0.19 g, 65%), which was used without further purification.

10 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): δ 10.40 (1H, s), 8.71 (1H, s), 7.38-7.26 (5H, m), 3.43 (s, 4H), 3.15 (bs, 1H), 2.86(3H, m), 2.55(1H, m), 2.00 (1H, m), 1.65 (3H, m), 1.30 (1H, m). HRFABMS Calcd for C<sub>15</sub>H<sub>21</sub>NO<sub>2</sub>SCs: 412.0347, found 412.0367.

**Preparation of compound 3b: cis-2-Phenethylsulfanyl-cyclohexanecarboxylic Acid.**

15 Obtained by heating a mixture of compound 3c (0.37g, 1.5 mmol), 2N H<sub>2</sub>SO<sub>4</sub> (2 mL), conc. H<sub>2</sub>SO<sub>4</sub> (4 mL), and dioxane (20 mL) at reflux for 14 hours. The solvent was evaporated and extracted with diethyl ether (2 x 30mL). The combined organic layers were washed with H<sub>2</sub>O (20 mL), brine (20 mL) and dried to give an oil (0.28 g) which was purified by column chromatography (70% ethanol/hexanes) to give 0.22 g (55%) of a viscous oil which slowly solidified on standing.


20 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.38-7.20 (5H, m), 3.36 (1H, bs), 2.91-2.74 (4H, m), 1.96(1H, m), 1.71 (6H, m), 1.50 (1H, m), 1.30 (1H, m). Anal. Calcd for C<sub>15</sub>H<sub>20</sub>O<sub>2</sub>S: C, 68.14; H, 7.62; S, 12.13. Found: C, 68.14, H, 7.66; S, 12.06.

Preparation of compound 3c: cis/trans-2-Phenethylsulfanyl-cyclohexane Carbonitrile.

A mixture of cyclohex-1-ene carbonitrile (1.61g, 15.0 mmol), and phenethyl mercaptan (6.0 mL, 45 mmol) in piperidine (30 mL) was combined in a pressure tube, evacuated, and heated at reflux for 6 h. The reaction mixture was then poured into 3N HCl (150 mL) and extracted with ethyl acetate (125 mL). The organic layer was washed with diethyl ether (150 mL), brine (150 mL), dried and concentrated to give a light orange oil, the cis/trans isomers were separated by column chromatography (10% ethyl acetate/hexanes) to give a total yield of 2.2 g (60% total), of which 1.16 g (80%) was the cis isomer.

5 cis isomer:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.33-7.20 (5H, m), 3.07(1H, bs), 2.86 (2H, bm), 2.69 (1H, bm), 2.10(1H, m), 1.90-1.50(6H, m), 1.30 (1H, m).

10 Anal. Calcd for  $\text{C}_{15}\text{H}_{19}\text{NS}$ : C, 73.42; H, 7.80; N, 5.70, S, 13.07. Found: C, 73.18; H, 7.80, N, 5.68; S, 13.04. Trans Isomer:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.36-7.12 (5H, m), 2.93 (2H, bm), 2.70 (1H, m), 2.54 (1H, m), 2.12 (2H, m), 1.74-1.58 (4H, m), 1.37 (2H, m).

Example 4: cis-Phenyl-ethanesulfonyl-cyclohexanecarboxylic Acid Hydroxyamide.

Prepared as described in Example 1, from compound 4a with a reaction time of 1 hour. Purification by column chromatography (ethyl acetate/trace Acetic acid) gave a white foamy solid (35%).

17  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.36-7.21 (5H, m), 3.30-2.90 (6H, m), 2.30 (1H, m), 2.10-1.85 (4H, m), 1.45(2H, m), 1.20 (1H, m). HRFABMS. Calcd for  $\text{C}_{15}\text{H}_{21}\text{NO}_4\text{SNa}$ : 334.1089, found 334.1082. Anal. ( $\text{C}_{15}\text{H}_{21}\text{NO}_4\text{S} \cdot 0.25 \text{H}_2\text{O}$ ) C, 57.03; H, 6.86; N, 4.43, S, 10.15. Found: C, 57.09; H, 6.87, N, 4.33; S, 10.04.

Preparation of compound 4a: cis-Phenylethanesulfonyl-cyclohexanecarboxylic Acid (O-Dimethyl-tert-butylsilyl)-hydroxyamide.


Prepared in the same fashion as compound 1a in Example 1 from compound 4b with a reaction time of 1 hour to give a colorless oil (89%), which was used without any further purification.

**Preparation of compound 4b: cis-2-Phenylethanesulfonyl-cyclohexanecarboxylic Acid.**

5 To a solution of compound 3b (from Example 3); 50 mg, 0.19 mmol) in methanol (1.5 mL) at 0°C was added a mixture of oxone (0.46 g, 0.76 mmol, 4 eq) in H<sub>2</sub>O (1.5 mL) in one portion. The resulting slurry stirred at ambient temperature for 65 h. Diluted with H<sub>2</sub>O (10 mL) and extracted with CHCl<sub>3</sub> (3 X 10 mL). The combined organic layers were dried and concentrated to give colorless oil (0.052 g, 93%), which was used without further purification.

10 <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.40-7.20 (5H, m), 3.45-3.10 (5H, m), 2.30 (1H, m), 2.20 (1H, m), 1.95 (2H, m), 1.55 (3H, m), 1.30 (2H, m).

**Example 5: trans-2-Phenylethanesulfonyl-cyclohexanecarboxylic Acid Hydroxyamide.**



15 Prepared in the same manner as Example 1, from compound 5a. Purification by column chromatography (ethyl acetate/trace Acetic acid) afforded a white solid (42%).  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  8.93 (1H, s), 7.36-7.35 (5H, m), 3.55-3.50 (1H, m), 3.40-3.25 (2H, m), 3.10-2.95 (3H, m), 2.50-2.35 (1H, m), 2.20-2.10 (1H, m), 1.80 (1H, bs), 1.75-1.70 (1H, m), 1.55-1.05 (4H, m). HRFABMS Calcd for C<sub>16</sub>H<sub>21</sub>NO<sub>4</sub>S: 312.1269, found 312.1280. Anal. Calcd for C<sub>16</sub>H<sub>21</sub>NO<sub>4</sub>S: C, 57.86; H, 6.80; N, 4.50; S, 10.30. Found, C, 57.77, H, 6.84; N, 4.51; S, 10.20.

20

**Preparation of compound 5a: trans-2-(2-Phenylethanesulfonyl)-cyclohexanecarboxylic Acid (O-Dimethyl-tert-butylsilyl)-hydroxamide**


Prepared in the same manner as compound 1a in Example 1, to give a colorless oil (79%), which was used without further purification.

25 **Preparation of compound 5b: trans-2-(2-Phenylethanesulfonyl)-cyclohexanecarboxylic Acid**

Prepared in the same manner as compound 3b in Example 3, from trans-2-(2-phenylethanesulfonyl)-cyclohexanecarboxylic acid in 18 hours to give a solid (70%) that was used without further purification.

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.35-7.15 (5H, m), 3.30-3.10 (5H, m), 2.90-2.75 (1H, m), 2.30-2.10 (2H, m), 1.95 (1H, m), 1.80-1.50 (4H, m), 1.30 (2H, m).

**Example 6. trans-2-(Biphenyl-4-yl-ethylsulfanyl)cyclohexanecarboxylic Acid Hydroxyamide.**



Prepared from compound 6a in the same fashion as Example 1. Upon attempted purification of the silylated hydroxamate by column chromatography (15-30% ethyl acetate/hexane), the deprotected title product had eluted instead as a white solid (49%).

10 <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  8.25 (1H, bs), 7.59-7.25 (9H, m), 2.90-2.79 (4H, m), 2.15 (1H, bs), 1.95-1.60 (7H, m), 1.35-1.15 (2H, m). HRFABMS. Calcd for C<sub>21</sub>H<sub>25</sub>O<sub>2</sub>SNa: 378.1504. Found 378.1512. Anal. Calcd for C<sub>21</sub>H<sub>25</sub>O<sub>2</sub>SN: C, 70.95; H, 7.09; N, 3.94; S, 9.02. Found C, 70.68; H, 7.06; N, 3.90; S, 9.21.

15 **Preparation of compound 6a: trans-2-(Biphenyl-4-yl-ethanesulfanyl)-cyclohexanecarboxylic Acid.**

Prepared in the same manner as compound 3b in Example 3, from compound 6b (from Example 6; 0.42 mmol) with 85% H<sub>3</sub>PO<sub>4</sub> (6 mL) and dioxane (4 mL) in place of H<sub>2</sub>SO<sub>4</sub>, a temperature of 135°C, and time of 5 days. Purified by column chromatography (30-50% ethyl acetate/hexanes) to give a solid (26%), which was used without further purification.

20 HRFABMS. Calcd for C<sub>21</sub>H<sub>25</sub>O<sub>2</sub>SNa: 341.1575. Found 341.1568.

**Preparation of compound 6b cis/trans-2-(Biphenyl-4-yl-ethanesulfanyl)-cyclohexanecarbonitrile**

Prepared in the same manner as compound 3c in Example 3, from compound 1e (from Example 1) after 21 hours stirring to give a 1:1 isomeric mixture (total yield 53%). The 25 isomers were separated by column chromatography (10-20% ethyl acetate/hexane).

cis-Isomer: <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.59-7.24 (9H, m), 3.09 (1H, m), 2.93-2.90 (4H, m), 2.72 (1H, m), 2.05 (1H, m), 1.95-1.56 (6H, m), 1.35 (1H, m). Trans-isomer: <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.60-7.29 (9H, m), 2.97 (4H, m), 2.73 (1H, m), 2.56 (1H, m), 2.10 (2H, m), 1.70-1.56 (4H, m), 1.50-1.30 (2H, m). Anal for mixture C<sub>21</sub>H<sub>23</sub>NS: C, 78.46; H, 7.21; N, 4.36; S, 9.97. Found C, 30 H, 7.21; N, 4.40; S, 9.88.

**Example 7: cis-2-(Biphenyl-4-yl-ethanesulfonyl)-cyclohexanecarboxylic Acid Hydroxamate.**

Prepared in the same fashion as in Example 1, from compound 7a. Purified by dissolution in methanol, evaporation to near dryness, followed by trituration with minimal ethyl acetate, and washing with diethyl ether to give a cream-colored solid (81%).

5  $^1\text{H}$  NMR (CDCl<sub>3</sub>):  $\delta$  10.60 (1H, s), 8.82 (1H, s), 7.71-7.40 (9H, m), 3.40-3.25(8H, m), 3.00 (1H, m), 2.75(1H, m), 2.50(1H, m), 1.90(1H, m), 1.60(1H, m), 1.35(1H, m). Anal. Calcd for C<sub>21</sub>H<sub>25</sub>O<sub>4</sub>S•0.25 H<sub>2</sub>O: C, 64.34; H, 6.56; N, 3.57, S, 8.18. Found: C, 64.38; H, 6.49, N, 3.47; S, 7.91. HRFABMS. Calcd for C<sub>21</sub>H<sub>25</sub>O<sub>4</sub>S Na 410.1402. Found: 410.1410.

Preparation of compound 7a: cis-2-(Biphenyl-4-yl-ethanesulfonyl)-cyclohexanecarboxylic Acid (O-Dimethyl-tert-butylsilyl)-hydroxamate.

10 Prepared in the same fashion as in Example 1, from compound 7b. Purification by column chromatography (ethyl acetate) afforded a white foamy solid (64%), which was used without further purification.

Preparation of compound 7b: cis-2-(biphenyl-4-yl-ethanesulfonyl)-cyclohexanecarboxylic acid

15 Prepared in the same fashion as compound 3b in Example 3, from the cis isomer of compound 7c after 4 days stirring. Purification by column chromatography (30-50% ethyl acetate/hexanes) gave viscous oil (68%).

1H NMR (CDCl<sub>3</sub>):  $\delta$  7.59-7.25 (9H, m), 3.35 (1H, bs), 2.92-2.74 (4H, m), 2.00-1.90 (1H, m), 1.78 (6H, m), 1.45(1H, m), 1.25 (1H, m). Anal. Calcd for C<sub>21</sub>H<sub>24</sub>O<sub>2</sub>S: C, 74.08; H, 7.10; S, 9.42. 20 Found: C, 73.85; H, 7.12; S, 9.54.

Preparation of compound 7c: cis-2-(biphenyl-4-yl-ethanesulfanyl)-cyclohexanecarboxylic acid

25 Prepared in the same fashion as compound 4b in Example 4, from compound 6b (from Example 6), after 18 hour stirring. Purification by column chromatography (ethyl acetate/trace Acetic acid) gave a solid (62%), which was used without further purification.

**HCV replicon assay:**

30 All compounds were tested in an HCV reporter replicon assay. Briefly, a reporter replicon containing Huh-7 hepatoma cells was grown in DMEM (Invitrogen, Carlsbad, CA) and seeded in 96-well black wall, clear-bottom plates (Costar®; Corning Incorporated). Cells were allowed to settle at 37°C, 5% CO<sub>2</sub> for 30 minutes. The compounds were serially diluted in separate 96 well plates and 100  $\mu$ l of each concentration was added to the appropriate well in triplicate. The plates are incubated at 37°C, 5% CO<sub>2</sub> for three days.

35 Following three days of incubation, the media was aspirated from the wells and cells are washed with 100  $\mu$ l PBS. After removing the PBS, 20  $\mu$ l of 1X Passive Lysis Buffer (Promega Corp., Madison, WI) is added to each well, and the cells are allowed to lyse at room temperature for 15 minutes. Antiviral activity and cytotoxicity is measured following lysis using the dual luciferase kit (Promega Corp., Madison, WI). The percent antiviral inhibition

and percent cytotoxicity for each concentration is calculated after subtracting the background values of media only wells from wells containing cells, and subtracting 100 from the percent ratio of the value in the compound well to the cell only control well. This results in the generation of effective concentrations of compounds where 50% antiviral inhibition is observed ( $EC_{50}$ ) and 50% cytotoxic concentration ( $CC_{50}$ ) of compounds.

5  $EC_{50}$  data as determined for exemplary compounds of the invention are presented in Table 1 below.

Table 1


X.	STRUCTURE	Extended 8-pt Assay				7-pt Assay						Activity
		EC50 ( $\mu$ M)	CC50 ( $\mu$ M)	TI	Solubility ( $\mu$ M)	EC50 ( $\mu$ M)	CC50 ( $\mu$ M)	CC50/ EC50	TI	Solu- bility	Solu- bility ( $\mu$ M)	
		1.9	41	21	<320	1.57	78	49	49.	320	>320	


Table 1

X.	STRUCTURE	Extended 8-pt Assay				7-pt Assay						Activity
		EC50 ( $\mu$ M)	CC50 ( $\mu$ M)	TI	Solubility ( $\mu$ M)	EC50 ( $\mu$ M)	CC50 ( $\mu$ M)	CC50/ EC50	TI	Solu- bility	Solubility ( $\mu$ M)	
		1.2	>320	>263	<320	1.5	>320	218	>218	32	<100	+
		0.018	79	4389	>320	0.097 (exp)	81	835	835.	320	>320	+
		0.19	224	1178	>320	0.15 (exp)	294	1937	1937.	320	>320	+
3		1.9	211	109	>320	2.5	320	130	>130	320	>320	+
		0.049	15	306	>320	0.027 (exp)	12	444	444.	320	>320	+
		0.26	>320	>1230	>320	0.36	320	880	888.	320	>320	+
		0.35	211	602	>320	0.44	293	667	666.	320	>320	+
1		1.6	31	19	>320	2.1	32	15	15.	100	<320	+
5		0.31	>320	>1032	>320	0.24 (exp)	>320	#VALU EI	>1333	320	>320	+
6		0.05	99	1980	>320	0.034 (exp)	111	3265	>3265	320	>320	+


While the invention has been described in terms of various preferred embodiments and specific examples, the invention should be understood as not being limited by the foregoing detailed description, but as being defined by the appended claims and their equivalents.

## WE CLAIM:

1. A method of interfering with or preventing HCV viral replication activity comprising contacting an HCV polymerase with a therapeutically effective amount of a hydroxamate MMP inhibitor.
- 5 2. A method of treating a condition that is mediated by HCV polymerase in a patient, comprising administering to said patient a pharmaceutically effective amount of a hydroxamate MMP inhibitor.
- 10 3. A method according to claim 1 further comprising the step of targeting MMP inhibition as a means of treating indications caused by HCV infections.
4. A method according to claim 1 further comprising the step of targeting viral or cellular targets identified by using MMP inhibitors for treating indications caused by HCV infections.
- 15 5. A method according to claim 1 further comprising the step of using MMP inhibitors for carrying out gene profiling experiments for monitoring the up or down regulation of genes for the purpose of identifying inhibitors for treating indications caused by HCV infections.
6. A pharmaceutical composition for the treatment of Hepatitis C virus (HCV) in a mammal comprising an amount of hydroxamate MMP inhibitor that is effective in treating HCV and a pharmaceutically acceptable carrier.
- 20 7. A method according to Claim 1 utilizing a hydroxamate MMP inhibitor of the formula I:




25 wherein:



R<sup>1</sup> is alkyl, aryl, halo, amino, substituted or distributed amino, or alkoxy;

and the pharmaceutically acceptable salts thereof.

8. A method according to Claim 1 utilizing a hydroxamate MMP inhibitor of the formula



wherein X is oxygen or C-CH<sub>2</sub>-.

9. A method according to Claim 7 wherein the hydroxamate MMP inhibitor is selected from the group consisting of:

- 5 2-(2-Phenylethyl)benzoic acid N-hydroxyamide;
- 2-(Propylthio)-pyridine-3-N-(hydroxy)carboxamide;
- [4-(N-Hydroxyamino)-2R-isobutyl-3S-((thien-2-ylthio)methyl)succinyl]-L-phenylalanine-N-methylamide;
- N-Hydroxy-5-phenylpentanamide;
- 10 2-(Phenyl-2-ethyl)pyridine-3-N-hydroxycarboxamide;
- 2-(Thiobenzyl)benzoic acid N-hydroxy amide;
- 6-Biphenyl-4-yl-[2,2-dimethyl-1-(pyridin-4-ylcarbamoyl)-propylcarbamoyl]-hexanoic acid, N-hydroxyamide;
- 3R(6-(4-Biphenyl)-3-(N-benzylcarbamoyl))-hexanoic acid N-hydroxyamide;
- 15 2-Benzylsulfonyl-cyclopent-1-ene-carboxylic acid hydroxyamide;
- 2-Benzylsulfonyl-cyclohex-1-enecarboxylic acid hydroxyamide;
- 6-Benzylsulfonyl-cyclohex-1-enecarboxylic acid hydroxyamide;
- 1-(N-Hydroxy)-3-(2-bibenzyl)urea;
- 3R-(6-(4-Biphenyl)propyl)-N-(3-methylpyridinecarbamoyl)- hexanoic acid N-hydroxy-amide;
- 20 4-(2-[[5-Hydroxyamino-3-(3-phenyl-propyl)-3,4-dihydro-2-H-pyrrole-3-carbonyl]-amino)-4-methyl-pentanoylamino)benzoic acid methyl ester;
- 5-Hydroxyamino-3-(3-phenyl-propyl)-3,4-dihydro-2-H-pyrrole-3- carboxylic acid (2-cyclohexyl-1-methylcarbamoyl-ethyl) amide;
- 4-(2- { [5-Hydroxyamino-3-(3-pentyl)-3,4-dihydro-2-H-pyrrole-3-carbonyl]-amino}-4-methyl-pentanoylamino) benzolic acid methyl ester;
- 25 6-Biphenyl-4-yl-3-(R)-(2-hydroxy-1-hydroxymethyl-ethylcarbamoyl)-hexanehydroxamic acid;
- 6-Biphenyl-4-yl-3(R)-(1(S)-hydroxymethyl-2,2-dimethyl- propylcarbamoyl)-hexanehydroxamicacid;
- 2-(Biphenyl-4-ylsulfonyl)-cyclohex-1-enecarboxylic acid hydroxyamide;
- 30 6-(Biphenyl-4-ylsulfonyl)-cyclohex-1-enecarboxylic acid hydroxyamide;
- 2-Phenethylsulfonyl-cyclohex-1-enecarboxylic acid hydroxyamide;
- 2-Benzylsulfonyl-cyclohexanecarboxylic acid hydroxamide;
- trans-2-Benzylsulfonyl-cyclohexanecarboxylic acid hydroxamide;

trans-2-(Biphenyl-4-yl-methylsulfanyl)-cyclohexancarboxylic acid hydroxamide;  
6-Biphenyl-4-yl-3-(R)-(1-hydroxymethyl-2-(S)-(1H-imidazol-4-yl)-ethylcarbamoyl)-hexanehydroxamic acid;  
N-Hydroxy-2-[2-Oxo-3-(3-phenyl-propyl)-tetrahydro-furan-3-yl]-acetamide;  
5 trans-2-(4-Phenoxy-benzylsulfanyl)-cyclohexancarboxylic acid hydroxamide;  
2-(4-Indol-1-yl-benzylsulfanyl)-cyclohexancarboxylic acid hydroxamide;  
2-(3-Biphenyl-4-yl-propyl)-N4-hydroxy-N1-(2,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl)-succinamide;  
2-(2-Biphenyl-4-yl-ethylsulfanyl)-cyclohexane carboxylic acid hydroxyamide;  
10 2-(3-Biphenyl-4-yl-propyl)-N4-hydroxy-N1-(2-hydroxy-cyclohexyl)-succinamide;  
6-Biphenyl-4-yl-3-(1-hydroxyimino-ethyl)-hexanoic acid hydroxyamide;  
3-(R)-(2-Hydroxy-1-(S)-(1H-imidazol-4-yl)-ethylcarbamoyl)-6-(4-(2-methyl-thiazol-4-yl)-phenyl)-hexanehydroxamic acid;  
6-Biphenyl-4-yl-3-(3-hydroxy-piperidine-1-carbonyl)-hexanoic acid-hydroxyamide;  
15 1-(4-Methoxy-benzenesulfonyl)-piperidine-2-carboxylic acid hydroxamide;  
1-1-[4-Bromo-phenoxy]-benzenesulfonyl)-piperidine-2-carboxylic acid hydroxyamide;  
N-(1-benzyl-2-hydroxy-ethyl)-N4-hydroxy-2-isobutyl- succinamide;  
6-Biphenyl-4-yl-3 (R)-2 (S)-hydroxy-(1(S)-hydroxymethyl-2,2-dimethyl-propylcarbamoyl)-hexanoic hydroxamic acid;  
20 6-Biphenyl-4-yl-3-(2-hydroxy-1hydroxymethyl-propylcarbamoyl)- hexanoic hydroxamic acid;  
trans-2-(3-Biphenyl-4-yl-propyl)-cyclohexane carboxylic acid hydroxyamide;  
1-[4-Biphenyl-4-yloxy)-benzenesulfonyl)-piperidine-2-carboxylic acid hydroxamide;  
1-(4-Phenoxy-benzenesulfonyl)-piperidine-2-carboxylic acid hydroxamide;  
6-Biphenyl-4-yl-3-(R)-(1-(S)-hydroxymethyl-2-(3-pyridyl)- ethylcarbamoyl)-hexanehydroxamic  
25 acid;  
6-Biphenyl-4-yl-2S-hydroxy-3R-(1S-hydroxymethyl-3- methylsulfanyl-propylcarbamoyl)-hexanoic hydroxamic acid;  
1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-4-(tertbutoxycarbonyl)-piperazine-2-carboxylic acid hydroxyamide;  
30 1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperazine-2-carboxylic acid hydroxamide;  
4-Acetyl-1-[4-phenoxy-benzenesulfonyl]-piperazine-2-carboxylic acid, N-hydroxyamide;  
1-(Diphenylphosphinic)-piperidine-2-carboxylic acid hydroxamide;  
6-Biphenyl-4-yl-3-(R)-(2-oxo-1-tetrahydrofuran-3-(S)-ylcarbamoyl)-hexane hydroxamic acid;  
1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-4-methyl-piperazine-2-carboxylic acid N-  
35 hydroxyamide;  
4-(4-Methoxy-benzenesulfonyl)-thiomorpholine-3-carboxylic acid hydroxyamide;  
3-(Diphenylphosphinic)-propanoic acid hydroxyamide;

1-[4-(4-Chlorophenoxy)benzenesulfonyl]-thiomorpholine-3-carbamoyl)piperazine-2-carboxamide;

4[4-Phenoxy-benzenesulfonyl]-piperazine-2-carboxylic acid, N-hydroxyamide;

4[4-Phenoxy-benzenesulfonyl]-thiomorpholine-3-carboxylic acid N-hydroxyamide;

5 3[2-Biphenyl-4-yl-ethylsulfanyl]-tetrahydro-pyran-4-carboxylic acid N-hydroxyamide;

1-[4-Phenoxy-benzenesulfonyl]-4-methyl-piperazine-2-carboxylic acid N-hydroxyamide;

6-Biphenyl-4-yl-3-(R)-(2-oxo-azepan-3-(S)-ylcarbamoyl)-hexane hydroxamic acid;

4-(1H-Indole-2-sulfonyl)-thiomorpholine-3-carboxylic acid hydroxyamide;

1-(Methyl-phenylphosphinic)-piperidine-2-(R)-carboxylic acid hydroxamide;

10 1-(1,3-Dihydro-Isolindole-2-sulfonyl)-piperidine-2-carboxylic acid hydroxamide;

4-Methyl-1-(4-(4-chlorophenyl)benzenesulfonyl)-N-hydroxy-2R- piperazinecarboxamide hydrochloride;

1-[4-Chlorophenoxybenzenesulfonyl]-N-hydroxy-2R-piperazinecarboxamide;

2-(3-Phenyl-propylsulfonyl)-cyclohexane carboxylic acid hydroxamate;

15 1-(Pyrrolidine-1-sulfonyl)-piperidine-2-carboxylic acid hydroxyamide;

1-(Piperidine-1-sulfonyl)-piperidine-2-carboxylic acid hydroxyamide;

4-[4-Bromo-phenoxy-benzenesulfonyl]-oxothiomorpholine-3-carboxylic acid-N-hydroxyamide;

1-[4-(4-Methoxy-phenylsulfanyl)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;

20 1-[4-(4-Cyano-phenoxy)-benzenesulfonyl]-4-(tert-butoxycarbonyl)-piperazine-2-carboxylic acid N-hydroxyamide;

6-Oxo-3-(4-phenoxy-benzenesulfonyl)-hexahydro-pyrimidine-4- carboxylic acid hydroxamate;

4-(t-Butoxycarbonyl)-1-(4-(pyridin-2-yl)oxybenzenesulfonyl)-N- hydroxy-piperazine-2-carboxamide;

25 4-[(4-Fluorophenoxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid N-hydroxyamide;

4-[4-(Fluoro-phenoxy)-benzenesulfonyl]-oxothiomorpholine-3-carboxylic acid N-hydroxyamide;

4-(4-Butoxy-benzenesulfonyl)-thiomorpholine-3-carboxylic acid hydroxyamide;

4-(4-Butoxy-benzenesulfonyl)-1-oxothiomorpholine-3-carboxylic acid hydroxyamide;

30 1-[4-(4-Fluorophenyl)benzenesulfonyl]-4-(tert-butoxycarbonyl)2R-piperazine-2-carboxylic acid hydroxyamide;

1-((4-(4-Chlorophenyl)-piperazine)-l-sulfonyl)-piperidine-2carboxylic acid hydroxamide;

cis-2-Phenethylsulfanyl-cyclohexanecarboxylic acid hydroxyamide;

1-[4-(4-Fluorophenyl) benzenesulfonyl]-N-hydroxy-2R- piperazinecarboxamide

35 hydrochloride;

1-(Diphenylphosphinic)-pyrrolidine-2(R)-carboxylic acid hydroxyamide;

trans-2-Phenethylsulfanyl-cyclohexanecarboxylic acid hydroxyamide;

1-[4-(4-Fluorophenyl)-piperazine- 1-sulfonyl]-piperidine-2- carboxylic acid hydroxamlde;

1-1-[4-(4-Fluorophenylsulfanyl)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;  
4-1-[4-(Bromo-phenoxy)-benzenesulfonyl]-2, 2-dimethyl-1-oxo-thiomorpholine-3-carboxylic acid hydroxyamide;  
1-(Pyrrolidine-1-carbonyl)-pyrrolidine-2 (R)-carboxylic acid hydroxyamide;  
5 R-4-[4-(Bromophenoxy)-benzenesulfonyl]-2,2-dimethyl- 1-oxo-thiomorpholine-3-carboxylic acid hydroxyamide;  
4-(Ethoxycarbonyl)methyl-1-(4-(4-chlorophenyl)benzenesulfonyl)-N-hydroxy-2R-piperazinecarboxamide hydrochloride;  
1-Phenethylcarbamoyl-pyrrolidine-2-(R)-carboxylic acid hydroxyamide;  
10 1-(4-Benzyl-piperazine-1-sulfonyl)-piperidine-2-carboxylic acid hydroxyamide;  
3(S)-N-Hydroxy-4-(4-(pyridin-4-yl) oxybenzenesulfonyl)-2, 2- dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide;  
2(R)-4-Methyl- 1-(4-(4-fluorophenyl)benzenesulfonyl)-N-hydroxy- piperazine-2-carboxamide;  
1-((2-Pyridyl)-4-piperazine- 1-sulfonyl)-piperidine-2-carboxylic acid hydroxyamide;  
15 1-1-[4-(Pyridin-4-ylsulfamyl)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;  
N-(4-Phenoxy-benzenesulfonyl)-D-tert-leucine-N-hydroxyamide;  
2,2-Dimethyl-4-[4-(pyridin-2-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide;  
N-1-[4-(4-Fluorophenoxy) benzenesulfonyl]-D-tert-leucine, N-hydroxyamide;  
20 3(R)-N-Hydroxy-4-(4-(pyridin-4-yl) oxybenzenesulfonyl)-2, 2- dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide hydrochloride;  
2-[4-(4-Chloro-phenoxy)-benzenesulfonylamino]-N-hydroxy-3,3-dimethyl-butyramide;  
3(R)-N-Hydroxy-4-(4-(fur-3-yl) phenoxybenzenesulfonyl)-2, 2- dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide;  
25 2-1-[4-(Pyridin-2-yl-oxy)-benzenesulfonylamino]-N-hydroxy-3, 3- dimethyl butyramide;  
2-(2-Biphenyl-4-yl-ethylsulfonyl)-cyclohex-1-ene-carboxylic acid hydroxyamide;  
6-(2-Biphenyl-4-yl-ethyl sulfonyl)-cyclohex-1-ene-carboxylic acid hydroxyamide;  
N-(4-Phenoxy-benzenesulfonyl)-3, 3-dimethyl-S-(methylthio)-D- cysteine, N-hydroxyamide;  
1- (4-Phenoxy-piperidine-1-sulfonyl)-piperidine-2-carboxylic acid hydroxyamide;  
30 N-(4-[4-Chlorophenoxy]-benzenesulfonyl)-3,3-dimethyl-S-(methylthio)-D-cysteine, N-hydroxyamide;  
N-(4-[4-Chlorophenoxy]-benzenesulfonyl)-3,3-dimethyl-S-(methylsulfoxy)-D-cysteine, N-hydroxyamide;  
cis-2-(2-Phenyl-ethanesulfonyl)-cyclohexanecarboxylic acid hydroxyamide;  
35 3(R)-N-Hydroxy-4-(4-(imidazol-1-yl) phenoxybenzenesulfonyl)-2, 2- dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide;  
3(R)-N-Hydroxy-4-(4-(pyridin-4-yl) oxybenzenesulfonyl)-2, 2- dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide;

4-1-[2-(2-Hydroxycarbamylmethyl-5-phenyl-pentanoylamino)-4-methyl-pentanoyl]-benzoic acid methyl ester;

trans-2-(2-Phenyl-ethanesulfonyl)-cyclohexanecarboxylic acid hydroxyamide;

3,3-Dimethyl-2-(4-phenoxy-phenylsulfanyl)methyl)-butyric acid, N-hydroxyamide;

5 2-(2-Biphenyl-4-yl-ethanesulfonyl)-cyclohexanecarboxylic acid hydroxamate;

2-[4-(4-Chlorophenyl)-piperazine-1-sulfonylamino]-3-methyl-3-(pyridin-2-ylmethylsulfanyl)-butyric acid N-hydroxyamide;

3,3-Dimethyl-2-(4-phenoxy-phenylsulfanyl)methyl)-butyric acid, N-hydroxyamide;

2(R)-[4-(4-Fluoro-phenoxy) benzenesulfonylamino]-3-methyl-3-(pyridin-2-yl sulfanyl)-butyric acid, hydroxyamide;

10 3(R)-N-Hydroxy-4-(4-((pyridin-4-yl) methyl) oxybenzenesulfonyl)-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide;

1-1-[4-(4-Chloro-phenoxy)-benzenesulfonyl]-4-(1-methyl-1H- imidazole-4-sulfonyl)-piperazine-2-carboxylic acid hydroxamide;

15 1-[4-(Pyridin-2-ylsulfanyl)-piperidine- 1-sulfonyl]-piperidine-2- carboxylic acid hydroxyamide;

2R-[4-(4-Furan-3-yl-phenoxy)-benzenesulfonylamino]-N-hydroxy-3-methyl-3-(pyridin-4-ylsulfanyl)-butyramide;

trans-2-(2-Biphenyl-4-yl-ethylsulfanyl)-cyclohexanecarboxylic acid hydroxyamide;

N4-(2, 2-Dimethyl-1 S-hydroxymethyl-propyl)-N1-hydroxy-3R [3-(4-pyridin-4-yl-phenyl)-pyrrol-20 1-yl]-succindiamide;

1-[4-(4-Fluoro-phenoxy)-benzenesulfonyl]-3,3-dimethyl-5-oxo-piperazine-2-carboxylic acid hydroxyamide;

2(R)-[4-(4-Iodo-phenoxy)benzenesulfonylamino]-3-methyl-(pyridin-3-yl-sulfonyl) butyric acid hydroxyamide;

25 1-[2-(Benzothiazol-2-ylsulfanyl)-piperidine-1-sulfonyl]-piperidine-2-carboxylic acid hydroxyamide;

5-[4-(4-Fluoro-phenoxy)-benzenesulfonyl]-4, 5, 6, 7-tetrahydro-3H-imidazolo[4,5,-c]pyridine-6-carboxylic acid hydroxyamide;

1-[4-(Pyridin-4-ylsulfanyl)-piperidine- 1-sulfanyl]-piperidine-2carboxylic acid hydroxyamide;

30 1-[4-(4-Methoxy-phenylsulfamyl)-piperidine-1-sulfonyl]piperidine-2-carboxylic acid hydroxyamide;

2(R)-[4-(4-Methylphenoxy)benzenesulfonylamino]-3-methyl-3-(pyridin-3-yl-sulfonyl) butyric acid hydroxyamide;

1-[4-(4-Methyl-phenylsulfamyl)-piperidine-1-sulfonyl]-piperidine- 2-carboxylic acid hydroxamide;

35 4-Methoxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide;

4-1-[4-(4-Chloro-phenoxy)-benzenesulfonyl]-2, 2-dimethyl- thiomorpholine-3-carboxylic acid hydroxyamide;

2 (R)-[4-(4-bromo-phenoxy) benzenesulfonylamino]-3-methyl-3-(pyridin-4-yl-sulfoxide) butyric acid hydroxyamide;

4-(4-Methoxy-benzensulfonyl)-2,2-dimethyl-1-oxo-thiomorpholine-3-carboxylic acid hydroxyamide;

5 4-4-(4-Chloro-phenoxy)-benzenesulfonyl]-2, 2-dimethoxy-1-oxo-thiomorpholine-3-carboxylic acid hydroxyamide;

3 (S)-2, 2-Dimethyl-4-[4-(pyridin-4-ylsulfanyl)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide;

10 3, 3-Dimethyl-N-hydroxy-2R-[-[4-(pyridin-4-ylsulfanyl)-piperidine- 1-sulfonylamino]-butyramide;

N-Hydroxy-2-[-(4-methylbenzenesulfonyl) amino] acetamide;

[4(-4-Imidazol-1-yl-phenoxy)-piperidine-1-sulfonyl]-piperidine- 2-carboxylic acid hydroxyamide;

15 1-[4-(4-Imidazol-1-yl-phenylsulfanyl)-piperidine-1-sulfonyl]-piperidine-2-carboxylic acid hydroxyamide;

2(R)-[4-(4-Chloro-benzoyl)-cyclohexanesulfonyl]-piperidine-1- carboxylic acid hydroxyamide;

1(R)-[4-(4-Chloro-benzoyl)-piperidine-1-sulfonyl]-piperidine-2- carboxylic acid hydroxyamide;

1(R)-(4-Pyridin-2-yl-piperazine-1-sulfonyl)-piperidine-2- carboxylic acid hydroxyamide;

1(R)-[4-(4-Imidazol-1-yl-phenoxy)-piperidine-1-sulfonyl]- piperidine-2-carboxylic acid

20 hydroxyamide;

N-Hydroxy-3,3-dimethyl-2R-[4(-(morpholine-4-carbonyl)-piperidine-1-sulfonylamino]-butyramide;

N-Hydroxy-3-methyl-3-(5-methyl-isoxazol-3-yl-methylsulfanyl)- 2R-[4-(pyridin-4-ylsulfanyl)-piperidine-sulfonylamino]-butyramide;

25 N-Hydroxy-2R-[4-(4-imidazol- 1-yl-phenoxy)-piperidine- 1-sulfonylamino]-3,3-dimethyl-butyramide;

2R-[4-(4-Chloro-benzoyl)-piperazine-1-sulfonylamino]-Nhydroxy-3-methyl-3-methylsulfanyl-butyramide;


N-Hydroxy-3-methyl-3-methylsulfanyl-2R-[4-(pyridin-4-ylsulfanyl)-piperidine-1-sulfonylamino]-


30 butyramide;

1R,3S,2,2-Dimethyl-1-oxo-4-[-[4-(pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide; and the pharmaceutically acceptable salts thereof.

10. A method according to Claim 1 wherein the hydroxamate MMP Inhibitor is selected from the group consisting of:

43






the pharmaceutically acceptable salts thereof.

5

11. A method according to Claim 1 wherein said hydroxamate MMP inhibitor is of the formula:



wherein:

10 Q is a divalent radical having four ring atoms which together with C\* and N form a six-membered ring, where each of said four ring atoms independently is unsubstituted or substituted by a suitable substituent, and at least one of said four ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; Ar is an aryl or heteroaryl group;

15 or the pharmaceutically acceptable salts thereof.


12. A method according to Claim 11 wherein said hydroxamate inhibitor is selected from the group consisting of:

2(R)-N-hydroxy-1-(4-(4-chlorophenoxy) benzenesulfonyl)-4-(methanesulfonyl)-piperazine-2-carboxamide;

20 2(R)-N-hydroxy-1-(4-(4-fluorophenoxy) benzenesulfonyl)-4-(methanesulfonyl)-piperazine-2-carboxamide;

3(S)-N-hydroxy-4-(4-((pyrid-4-yl) oxy)benzenesulfonyl)-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide;  
and the pharmaceutically acceptable salts thereof.

13. A method according to Claim 1 wherein said hydroxamate inhibitor is of the  
5 formula:



wherein Y is O or S;

Ar is an aryl group or a heteroaryl group;

R is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a  
10 heteroaryl group, or -C(O)R1,

wherein R1 is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or NR2 R3, wherein R2 and R3 independently are hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group; or the pharmaceutically acceptable salts thereof.

15 14. A method according to Claim 13, wherein said hydroxamate inhibitor is selected from the group consisting of:

2(S)-N-hydroxy-3,3-dimethyl-2-[(4-(4-fluorophenoxy)benzenesulfonyl)-amino]butanamide;

2(S)-N-hydroxy-3,3-dimethyl-2-[(4-(4-chlorophenoxy)benzenesulfonyl)-amino]butanamide;

20 2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-fluorophenoxy)benzenesulfonyl)-amino]butanamide;

2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-bromophenoxy)benzenesulfonyl)-amino]butanamide;

2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-iodophenoxy)benzenesulfonyl)-amino]butanamide;

25 2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-(4-fluorophenoxy)benzenesulfonyl)-amino]butanamide;

2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-(4-bromophenoxy)benzenesulfonyl)-amino]butanamide;

30 2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-methylphenoxy)benzenesulfonyl)-amino]butanamide;

2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-(pyrid-4-yloxy)benzenesulfonyl)-amino]butanamide;

2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-((pyrid-4-yl)sulfanyl)-benzenesulfonyl)amino]butanamide;

2(S)-N-hydroxy-3-methyl-3-(1H-imidazol-4-yl)methylsulfanyl-2-[(4-(4-bromophenoxy)benzenesulfonyl)-amino]butanamide;

5 2(S)-N-hydroxy-3-methyl-3-(1-methyl-1H-1imidazol-2-yl) methylsulfanyl-2-[(4-(4-bromophenoxy)-benzenesulfonyl)amino]butanamide;


2(S)-N-hydroxy-3-methyl-3-(1-methyl-1H-1imidazol-4-yl) methylsulfanyl-2-[(4-(4-bromophenoxy)-benzenesulfonyl)amino]butanamide;

10 2(S)-N-hydroxy-3-methyl-3-(4-methyl-4H-[1,2,4]-triazol-3-yl) methylsulfanyl-2-[(4-(4-bromophenoxy)-benzenesulfonyl)amino]butanamide;


2(S)-N-hydroxy-3-methyl-3-methylsulfanyl-2-[(4-(4-chlorophenoxy)benzenesulfonyl)amino]butanamide; and the pharmaceutically acceptable salts thereof.

15

15. A method according to Claim 1 wherein said hydroxamate MMP inhibitor is selected from the group consisting of:



47



and the pharmaceutically acceptable salts thereof.

5

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**